Epigenetic regulation of micrornas in prostate cancer by João Álvaro Barbosa Martins
  
 
 
 
 
EPIGENETIC REGULATION 
OF MICRORNAS IN PROSTATE CANCER 
 
 
 
 
by 
 
JOÃO BARBOSA MARTINS 
 
Dissertation to a Master’s Degree in Oncology 
 
 
2012 
II 
 
  
III 
 
 
 
João Álvaro Barbosa Martins 
 
 
EPIGENETIC REGULATION OF MICRORNAS IN PROSTATE 
CANCER 
 
 
 
Dissertation for applying to a Master’s Degree in Oncology - 
Specialization in Molecular Oncology submitted to the Institute of 
Biomedical Sciences Abel Salazar – University of Porto 
 
 
Supervisor: Rui Manuel Ferreira Henrique, MD, PhD 
Guest Assistant Professor 
Department of Pathology and Molecular Immunology 
Institute of Biomedical Sciences Abel Salazar – University of Porto 
Director of Department of Pathology and senior researcher at the Cancer 
Epigenetics Group of the Research Center 
Portuguese Oncology Institute – Porto 
 
Co-Supervisor: Cármen de Lurdes Fonseca Jerónimo, PhD 
Guest Associate Professor 
Department of Pathology and Molecular Immunology 
Institute of Biomedical Sciences Abel Salazar – University of Porto 
Assistant Investigator and Coordinator of the Cancer Epigenetics Group  
Department of Genetics and Research Center 
Portuguese Oncology Institute – Porto 
IV 
 
  
V 
 
AKNOWLEDGMENTS 
 
In the first, place I would like to thank Prof. Rui Henrique for the opportunity 
provided of making research in such a recognized group such as Cancer Epigenetics 
Group, for receiving the supervision of this Thesis, for all the time and patience spent with 
me and my work and for all the support and dedication provided. I am mostly thanked for 
all comprehension, dedication, confidence and constant encouragement to achieve the 
aims purposed. In fact, this past year was very demanding as I had to conciliate laboratory 
research with my work as a pharmacist in I.P.O.F.G.-Porto Pharmacy, but now looking 
back I realize it worth it. Thank you for the great opportunity to enrich my knowledge on 
molecular biology and I am positively sure that it will have a great impact in my 
professional future.  
 
I also want to thank to my co-supervisor Prof. Carmen Jerónimo for sharing all her 
knowledge and I am certain that with her expertise in Epigenetics, this work will be much 
more enriched. Thank you both for all patience for reading and reviewing this Thesis.  
 
To Prof. Carlos Lopes former Director of Oncology Master’s Programme for all the 
precious knowledge and experience shared during the first year of this Master Programme 
and also to Prof. Berta Silva actual Director, for all the help provided. 
 
A very special thanks to João Ramalho Carvalho and Pedro Pinheiro, for all the 
assistance provided, not only in laboratorial settings but also in results interpretation and 
development of this work. Thank to both of you for all the knowledge, hours, patient and 
optimism provided to me and my research, without which its success couldn’t be 
achieved.  
 
Other very special thank to Ana Oliveira, Filipa Vieira, Inês Graça, Elsa Sousa, 
Tiago Batista, Natalia Costa, Susana Neto, Sara Reis and all other members of Cancer 
Epigenetics Group for your conviviality, availability, help and suggestions that much have 
contributed to the success of this project. To all other colleagues of the Department of 
Genetics for the great environment provided, especially to Nuno, Sofia, Isabel and Diogo.      
 
I would like to give a special praise to all my Oncology Master’s class, especially 
Diana Mesquita for all her patience and dedication, which made this step in our academic 
life so much easier. I also want to pay tribute to Ana Sarmento, Ana São João, Michel, 
VI 
 
José Fernandes, Rui, Ida, Isa and all the others for their friendship and to wish them the 
best luck in professional and personal life.  
 
More personally I would like to give a special thank to my entire family for all the 
love, education and support provided during my entire life, which allowed me to become 
what I am today. A great and special thank to my mother, once all I became and 
conquered in life I owe to her and her constant dedication to me. 
 
Finally, I would like to thank all my friends, especially those from F.F.U.P. and 
C.E.S.P.U., for having provided me wonderful moments, once life isn’t just science. A 
special thank to José Moura, for all the hours we spent learning with each other and 
discussing science during my degree and during this Master Programme. 
 
A special praise to you all, this Thesis is dedicated to you. 
 
  
 
This study was funded by grants from Research Center of Portuguese Oncology 
Institute-Porto (Project CI-IPOP-4), and from the European Community’s Seventh 
Framework Programme – Grant number FP7-HEALTH-F5-2009-241783. 
 
  
VII 
 
RELEVANT ABBREVIATIONS 
 
5-AZA-DC  5-Aza-2'-Deoxycytidine  
ACTβ   Actin β 
AR   Androgen Receptor 
AUC   Area Under the Curve 
CpG   Cytosine-phosphate-Guanine 
DNA   Deoxyribonucleic Acid 
DNMTs  DNA methyltransferases 
GS   Gleason’s Score 
HD   Healthy Donors  
HDAC   Histone Deacetylases 
HGPIN  High Grade Prostatic Intraepithelial Neoplasia 
miRISC  MiRNA-containing RNA-Induced Silencing Complex 
MiRNA  MicroRNA 
mRNA   Messenger RNA 
MSP   Methylation Specific Polymerase Chain Reaction 
NPT   Normal Prostatic Tissue 
NPV   Negative Predictive Value 
PCa   Prostate Cancer 
PCR   Polymerase Chain Reaction 
PIA   Proliferative Inflammatory Atrophy 
PPV   Positive Predictive Value 
PSA   Prostate Specific Antigen 
qMSP Real-time Quantitative Methylation-Specific Polymerase Chain 
Reaction 
qRT-PCR  Quantitative Reverse-Transcriptase Polymerase Chain Reaction 
RNA   Ribonucleic Acid   
ROC   Receiver Operator Characteristics 
VIII 
 
TGF-β   Transforming Growth Factor β 
UTR   Untranslated Region 
   
IX 
 
SUMMARY 
 
BACKGROUND: Prostate cancer (PCa) is one of the most prevalent cancers worldwide, 
constituting a serious health problem. Clinically localized disease might be successfully 
treated whereas disseminated disease remains mostly lethal. PCa is thought to be the 
end product of the interaction of environmental, physiological and molecular/genetic 
factors. Over the last decade, the role of epigenetic alterations in prostate carcinogenesis 
has emerged and provided a new framework for the understanding of the mechanisms 
underlying the disease as well as for the development of novel PCa biomarkers. Although 
aberrant DNA methylation and post-transcriptional histone modifications have been the 
main focus of epigenetic-oriented research in PCa, the role of microRNAs (miRNA) 
deregulation has more recently surfaced. These are small, single-stranded, non-coding, 
untranslated RNAs that control gene expression at the post-transcriptional level, 
interacting directly with messenger RNA (mRNA). MiRNAs are globally downregulated in 
most cancers and although genetic mechanisms have been appointed as the main cause, 
a role for epigenetic disruption of miRNAs regulation has been recently emphasized. 
 
AIMS: The main aim of this Thesis was to identify new epigenetically downregulated 
miRNAs in PCa, using an expression profiling based approach, followed by validation in a 
larger set of clinical samples. In addition, we attempted to identify novel PCa biomarkers 
suitable for clinical application in early detection, diagnosis and prognosis assessment. 
 
METHODOLOGIES: In silico analyses were performed in ten PCa against four 
morphologically normal prostatic tissues (NPT) based on gene expression profiling data of 
740 miRNAs. MiRNAs significantly downregulated in that analysis and re-expressed after 
treatment with an epigenetic-modulating drug in at least two of three cell lines, were 
selected for further analysis. Subsequently, candidate miRNAs were surveyed for the 
presence of a CpG island up to 5000 bp upstream of their mature sequence. Candidate 
miRNAs fulfilling all these requirements were then validated through DNA methylation 
analysis in a larger series of tissue samples comprising PCa, NPT and high-grade 
prostatic intraepithelial neoplasias (HGPIN). Real-time quantitative methylation-specific 
polymerase chain reaction (qMSP) analysis of 101 PCa, 14 NPT and 56 HGPIN allowed 
for the determination of promoter methylation levels of the selected miRNAs. Correlation 
between methylation levels, on the one hand, and expression levels and standard 
clinicopathologic parameters, on the other hand, was performed. Methylation levels were 
also used to assess miRNAs performance as PCa biomarkers in tissue samples, and the 
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best performing miRNAs were then selected for the same type of analysis in urine, using 
39 samples from PCa, and 15 samples from donors (HD) as controls. Finally, putative 
pathways targeted by the epigenetically deregulated miRNAs were also examined to 
provide a biological rational for their role in prostate carcinogenesis. 
 
RESULTS AND DISCUSSION: Expression profiling identified 173 differently expressed 
miRNAs out of 740. Of these 173, 47 were considered significantly downregulated and 5 
upregulated, comparing PCa to NPT. Concerning response to demethylating treatment, 
18 and 120 miRNAs were commonly re-expressed in three and two cell lines, 
respectively. Combining both datasets and looking for the presence of a CpG island at the 
promoter region, miR-130a, miR-145 and miR-205 surfaced as the best candidates for 
further validation. Methylation analyses revealed that their promoter was frequently 
methylated in PCa tissue compared to NPT, and that alteration was already apparent in 
HGPIN. However, miR-145 was not shown to be significantly downregulated in most PCa 
tissue samples, contrarily to the other two miRNAs. Unexpectedly, there was no 
significant correlation between promoter methylation and expression levels, suggesting 
that other epigenetic mechanisms might be also involved in altered expression of these 
miRNAs. Furthermore, expression levels of miR-205 correlated with Gleason’s score and 
clinical stage, which may be indicative of a potential role as marker of disease 
aggressiveness. A quantitative assay for promoter methylation of miR-130a and miR-205 
displayed high sensitivity and specificity for the discrimination between PCa and NPT 
(89.11% and 100%, respectively), with an overall accuracy of 90.43% and an area under 
the curve (AUC) of 0.970. These promising results were further tested in urine samples. 
Although the sensitivity of the urine assay was modest (25.64%), it was demonstrated for 
the first time that miRNAs promoter methylation levels may be successfully detected in 
body fluids of PCa. Because miRNA promoter methylation levels were identified in HGPIN 
lesions, it is suggested that this epigenetic aberration is an early event in prostate 
carcinogenesis. The three miRNAs analyzed in this study are predicted to be involved in 
the regulation of several key cellular pathways including signal transduction, transcription 
factors, apoptosis and cell adhesion, suggesting a role for miR-130a, miR-145 and miR-
205 epigenetic deregulation in prostate carcinogenesis. 
 
CONCLUSIONS: Downregulation of miRNAs due to epigenetic deregulation seems to 
be an infrequent event in PCa. However, promoter methylation of miR-130a, miR-145 and 
miR-205, occur early in prostate carcinogenesis and might provide novel biomarkers for 
PCa detection and diagnosis. Further studies are required to illuminate the biological role 
of these alterations in PCa initiation and progression.   
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RESUMO 
 
INTRODUÇÃO: O cancro da próstata é uma das neoplasias mais prevalentes 
mundialmente, constituindo um grave problema de saúde. A doença clinicamente 
localizada pode ser tratada com sucesso, enquanto que a doença disseminada é na 
maioria dos casos fatal. Pensa-se que o cancro da próstata seja o produto final da 
interação de fatores ambientais, fisiológicos e moleculares/genéticos. Ao longo da última 
década, o papel das alterações epigenéticas na carcinogénese prostática tem ganho 
enorme relevância e tem constituído uma fonte sólida de novas bases para entender 
alguns dos mecanismos relacionados com a doença, e ainda o desenvolvimento de 
novos biomarcadores. Apesar de alterações como a metilação aberrante do DNA e a 
modificação pós-transcricional das histonas ter vindo a ser o principal foco dos estudos 
epigenéticos em cancro da próstata, recentemente a desregulação patológica dos 
microRNAs tem recebido enorme importância e atenção. Estas pequenas sequencias de 
RNA de cadeia única, não codificante e não traduzidas controlam a expressão genética 
pós-transcricional, interagindo directamente com o mRNA. Os microRNAs encontram-se 
globalmente sub-expressos em muitos cancros e apesar de alterações genéticas terem 
vindo a ser apontadas como a principal causa, a regulação epigenética dos microRNAs, 
tem vindo a receber especial atenção.           
 
OBJECTIVOS: O principal objetivo desta Tese foi identificar novos microRNAs sub-
expressos em cancro da próstata, devido a mecanismos epigenéticos, recorrendo a uma 
análise de perfil de expressão, seguida de uma validação num elevado número de 
amostras clínicas. Tentamos ainda identificar novos biomarcadores para cancro da 
próstata, passiveis de serem utilizados em deteção e diagnóstico precoce e avaliação de 
prognóstico.   
 
METODOLOGIAS: Efetuou-se uma análise in silico, comparando dez tecidos de 
adenocarcinoma prostático com quatro tecidos prostáticos morfologicamente normais 
baseada nos resultados da análise do perfil de expressão de 740 microRNAs. Aqueles 
significativamente sub-expressos na análise e que demonstraram ser re-expressos após 
tratamento com um fármaco modulador epigenético em pelo menos duas ou três linhas 
celulares, foram selecionados para os estudos seguintes. Subsequentemente, os 
microRNAs candidatos foram examinados acerca da presença de uma ilha CpG até 5000 
pares de bases acima da sua sequência madura. Os microRNA candidatos que 
cumpriam todos estes requisitos foram validados através da análise do estado de 
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metilação do seu promotor em séries maiores de amostras de tecidos de 
adenocarcinoma prostático, tecido prostático morfologicamente normal e tecidos de 
neoplasia intra-epitelial. Uma metodologia de PCR específica para quantificação de 
metilação foi efetuada em 101 amostras de tecido de adenocarncinoma prostático, 14 
tecidos prostáticos morfologicamente normais e 56 tecidos de neoplasia intra-epitelial, 
permitindo a determinação dos níveis de metilação do promotor dos microRNAs 
selecionados. Foi também pesquisada uma correlação entre os níveis de metilação, os 
níveis de expressão e características fisiopatológicas padrão. Os níveis de metilação 
foram também utilizados para avaliar a performance dos miRNAs selecionados como 
biomarcadores em amostras de tecido e os mais promissores foram estudados em 
amostras de urina, utilizando o mesmo tipo de análise, em 39 amostras de 
adenocarcinoma prostático e 15 amostras de dadores saudáveis como controle. 
Finalmente, potenciais vias alvo dos microRNAs epigeneticamente regulados foram 
examinadas, de forma a avaliar o seu impacto na carcinogénese prostática.    
 
RESULTADOS E DISCUSSÃO: A análise do perfil de expressão dos 740 microRNAs 
identificou 173 expressos diferentemente. Destes 173, 47 foram considerados como 
significativamente sub-expressos e 5 sobre-expressos, comparando adenocarncinoma 
prostático e tecidos prostático morfologicamente normal. Relativamente à resposta ao 
agente desmetilante, 18 e 120 microRNAs foram comummente re-expressos em três e 
duas linhas celulares, respetivamente. Combinando os resultados e a pesquisa da 
presença de uma ilha CpG na região do promotor o miR-130a, miR-145 e miR-205 
revelaram ser candidatos promissores para posterior validação. A análise de metilação 
revelou que os seus promotores estão frequentemente metilados em cancro da próstata 
quando comparado com tecido prostático morfologicamente normal, e que esta alteração 
era já aparente em neoplasia intra-epitelial. Contudo o miR-145 não demonstrou estar 
significativamente sub-expresso na maioria das amostras de adenocarcinoma, ao 
contrário dos outros dois microRNAs. Inesperadamente não foi aparente uma correlação 
significativa entre a metilação do promotor e os níveis de expressão, sugerindo que 
outros mecanismos epigenéticos possam também estar envolvidos na alteração da 
expressão desses microRNAs. Além disso, os níveis de expressão do miR-205 
correlacionaram-se com a pontuação de Gleason e com o estadiamento clínico, o que 
pode ser indicativo de um potencial papel como marcador da agressividade da doença. A 
análise quantitativa da metilação do promotor do miR-130a e do miR-205 revelou uma 
elevada sensibilidade e especificidade em discriminar adenocarcinoma prostático e tecido 
morfologicamente normal (89.11% e 100%, respetivamente), com uma precisão de 
90.43% e uma área sobre a curva de 0.970. estes resultados promissores foram então 
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testados em amostras de urina. Apesar de a sensibilidade demonstrada nos estudos em 
urina ser modesta (25.64%), demonstrou-se pela primeira vez que os níveis de metilação 
do promotor de microRNAs podem ser detetados com sucesso em fluidos biológicos de 
pacientes com cancro da próstata. Uma vez que níveis de metilação do promotor foram 
identificados como já estando elevados em neoplasia intra-epitelial, sugere que esta 
alteração epigenética possa constituir um evento precoce na carcinogénese prostática. 
Os três microRNAs analisados neste estudo parecem estar envolvidos na regulação de 
diversas vias celulares importantes tais como transdução de sinal, fatores de transcrição, 
apoptose e adesão celular, sugerindo um papel importante da desregulação epigenética 
do miR-130a, miR-145 e miR-205 na carcinogénese prostática.      
 
CONCLUSÕES: A sub-expressão de microRNAs devido a alterações epigenéticas 
parece ser bastante infrequente em cancro da próstata. Contudo, a metilação do 
promotor do miR-130a, miR-145 e miR-205 parece ocorrer precocemente na 
carcinogénese prostática e pode fornecer novos biomarcadores para a deteção e 
diagnóstico da doença. Futuros estudos são necessários para elucidar a função biológica 
destas alterações na iniciação e progressão desta doença.   
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INTRODUCTION 
Prostate Cancer 
Epidemiology 
Nowadays, cancer is one of the most common health problems, with a register of  
12.7 million cases and responsible for 7.6 million cancer deaths all around the world in 
2008 (Jemal et al., 2011). 
Worldwide, prostate cancer (PCa) constitutes one of the three most common 
cancers among male (Siegel et al., 2012), is the second most commonly diagnosed 
neoplasia and the sixth leading cause of cancer death in males (Jemal et al., 2011), 
despite all the recent improvements in diagnosis and treatment. Indeed, in spite of men’s 
long lifetime represent a high risk to develop this disease (about 16–18%), the 
corresponding risk of death is only about 3% (Fleshner et al., 2012). In fact, international 
data reveals that PCa accounted for 14% (903,500) of the total new cancer cases and 6% 
(258,400) of the total cancer deaths in men in 2008 (Jemal et al., 2011). Its incidence 
rates vary by more than 25-fold worldwide as the develop countries (Oceania, Europe and 
North America) record highest rates when compared to less develop countries of Africa or 
the Caribbean region. On the other hand, the highest mortality rates are verified in the 
less developed countries (Fig. 1 and 2) (Jemal et al., 2011, Center et al., 2012). Indeed, 
this different global distribution and prognosis may be connected to population’s genetic 
profiles or even to different diagnosis or detection methodologies (Jemal et al., 2011). 
Concerning Portugal, the last statistics available revealed PCa as the most 
incident neoplasia in men, with 5140 cases in 2008, however being the third most lethal 
cancer (Ferlay et al., 2010) (Fig. 3). 
 
 
 
 
 
 
 
 
Figure 1 – Most commonly diagnosed cancers among men worldwide. Adapted from (Center et al., 2012) 
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Figure 2 – Age-standardized PCa incidence and mortality rates by geographic area. Adapted from (Jemal et 
al., 2011) 
 
 
 
Figure 3 – Incidence and mortality of different types of cancers in Portugal (number of newly 
diagnosed cancers cases and proportion for each cancer comparing to all types of cancer in both genders). 
Adapted from (Ferlay et al., 2010) 
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Clinical Disease and Diagnosis 
Prostate is a male exocrine retroperitoneal organ, encircling the neck of the 
bladder and urethra, which in the normal adult weighs approximately 20 g and is devoid of 
a distinct capsule (McNeal, 1981). Prostatic parenchyma can be divided into four 
biologically and anatomically different regions or zones: the peripheral, central and 
transitional zones and the region of the anterior fibromuscular stroma (McLaughlin et al., 
2005) (Fig. 4). Indeed, the central zone surrounding the ejaculatory ducts is the dominant 
zone for benign hyperplasia development, while the peripheral zone harbors the majority 
of prostate carcinomas (75%) (McLaughlin et al., 2005, Shen and Abate-Shen, 2010). 
This organ’s main function is to produce and secrete an alkaline fluid, named seminal 
fluid, which forms part of the ejaculate, aiding spermatozoids motility and nourishment 
(Dunn and Kazer, 2011). 
 
  
 
 
 
 
 
 
 
Figure 4 – Zonal anatomy of the normal prostate. (A) Young male with minimal transition zone hypertrophy. 
(B) Older male with transition zone hypertrophy, which effaces the pre-prostatic sphincter and compresses the peri-
ejaculatory duct zone. Abbreviations: AFS - Anterior Fibromuscular Stroma; CZ - Central Zone; PZ - Peripheral Zone; 
SV - Seminal Vesicle; TZ - Transition Zone. Adapted from (McLaughlin et al., 2005) 
 
Concerning the clinical features of PCa, the localized disease is often 
asymptomatic, but occasionally it may have some of the same symptoms as the benign 
hyperplasia, including weak stream, hesitant, urgent and frequent need to urinate, 
nocturia, incomplete emptying and various degrees of incontinence (Dunn and Kazer, 
2011). The clinical condition may also include hematuria, hematospermia, elevated PSA 
levels, erectile dysfunction (Dunn and Kazer, 2011) and the diagnosis is confirmed by 
rectal and physical examination and finally needle biopsy. Advanced clinical disease is 
characterized by bony pain, especially in the hips and pelvis has a cause of metastasis 
(Dunn and Kazer, 2011). 
(SV) 
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This malignancy has been recognized as a clinical problem, since ancient Egypt, 
when it was firstly described, however, effective treatment by surgical procedures 
(prostatectomy) were only developed in the last century (Capasso, 2005). Concerning 
PCa diagnosis, the highly accessible blood test for prostate-specific antigen (PSA) 
constituted the greatest improvement over the past three decades (Shen and Abate-Shen, 
2010, Hernandez and Thompson, 2004). This kallikrein-related serine protease is 
produced in normal prostate secretions, however is released into the blood stream when 
the normal prostate architecture is disrupted (Lilja et al., 2008). Elevated PSA, which the 
upper limit that has been considered is 4.0 ng/mL (Hernandez and Thompson, 2004), is 
usually the primary suspicion criteria for digital rectal examination and undergoing biopsy. 
In fact, studies like European Randomized Study of Screening for Prostate Cancer where 
a group of men invited for PCa screening based on PSA was compared to a control group 
without no active intervention (Schroder et al., 2009), demonstrated that, after a median 
follow-up of 9 years, men randomized to active surveillance, had a significant reduction in 
PCa mortality; ratio rate (RR) 0.80 (95% CI 0.65–0.98; adjusted p=0.04) (Schroder et al., 
2009). In the same line, other studies revealed the same, like the Göteborg Randomized 
Population-based Prostate Cancer Screening Trial, in which a group of 20,000 men was 
divided in half and randomized to a screening program for PSA testing every 2 years 
against the other half, which was not included in the screening program, serving as a 
control (Hugosson et al., 2010). In addition, men in the screening group whose PSA 
concentrations were elevated, were offered additional tests such as digital rectal 
examination and prostate biopsies (Hugosson et al., 2010). The results of this trial showed 
that during a median follow up of 14 years, PCa incidence was 12.7% in the screening 
group and 8.2% in the control group; hazard ratio 1.64 (95% CI 1.50–1.80; p<0.0001) 
(Hugosson et al., 2010). Also the absolute cumulative risk reduction of death from PCa at 
14 years was 0.40% for the control group against the screening group, added to the RR 
for death from this disease which was 0.56 (95% CI 0.39–0.82; p=0.002) in the screening 
group compared to the control group (Hugosson et al., 2010). Results from these studies, 
provide strong evidence that PSA based PCa screening may reduce its mortality. In fact 
PSA isn’t only associated to diagnosis, as it also constitutes a clinical weapon to assay 
treatment response, once it can be used to evaluate the response to hormonal therapy 
and to predict disease recurrence, especially after radical prostatectomy (Lilja et al., 2008, 
Lange et al., 1989). 
However, screening based on PSA to diagnosis intends, may have some 
limitations because it may lead to overdiagnosis and overtreatment, due to its lack of 
sensitivity and specificity (Henrique and Jeronimo, 2004). Interestingly, some problems 
have been raised by the scientific community as only 1 in 4 men with PSA levels higher 
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than 4.0 ng/mL would be found to have PCa, while the other 3 here unnecessarily 
biopsied (Hernandez and Thompson, 2004). Moreover, other PSA values and parameters 
have emerge in order to overcome PSA lack of sensitivity such as PSA velocity, volume-
related PSA, transition zone PSA, PSA density and ratio of free-to-total PSA, however 
none of those provide a satisfactory sensibility and/or sensitivity (Hernandez and 
Thompson, 2004, Carter et al., 2007, Bunting, 2002). In addition, adjustments have been 
proposed, in accordance with age (Gustafsson et al., 1998). Despite all this, PSA is still 
widely used in the screening of PCa as other clinical biomarkers slow to emerge. In fact, 
in the last few years, several biomarkers have been suggested in order to promote 
diagnosis or predict prognosis, such as Human Kallikrein 2, Prostate-specific membrane 
antigen, presence of fusions genes, between others, however much is still to be known 
and verified before including them in clinical practice (You et al., 2010). 
After biochemical evaluation and physical confirmation, needle biopsy is 
performed, followed by pathological analysis based on histopathological grading of the 
tissue. This evaluation is performed by Gleason scoring, which classifies tumors from 2 to 
10 concerning tissue architecture, with minimal consideration of tumor cell morphology 
(Gleason and Mellinger, 1974, Yu and Luo, 2007). This scoring allows two grades by 
tumor sample and after combination of them, as one reflects dominant architectural 
pattern and the other a minor architectural pattern, it generates a final Gleason’s score. In 
this way, a tumor sample with combined Gleason’s score between 2 – 4 is considered well 
differentiated, 5 – 6 moderately and 7 – 10 poorly differentiated. In fact, Gleason scoring 
may constitute a powerful tool in predicting outcome after radical prostatectomy, radiation 
and hormonal therapy and also a helpful instrument for choosing the best therapeutic 
approach (Shah, 2009). Indeed, patients with low Gleason score (6 or lower) are often 
recommended for active surveillance, in the meanwhile, those with a score of 7 are 
indicated for therapy of any kind, finally those with a score between 8-10 are candidates 
for adjuvant therapy or radiation treatment (Shah, 2009). 
The diagnosis also includes the status of the primary tumor, from organ confined to 
fully invasive (T1 – 4), with or without lymph node impairment (N0 or 1) and the presence 
of distant metastasis (M0 and 1) (Ohori et al., 1994). 
 
 
Treatment 
Concerning treatment, localized disease may be effectively suppressed by surgical 
excision of total organ – radical prostatectomy – or irradiation through external or 
internal/implanted beam radiation – brachytherapy, however metastatic disease remains 
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incurable and fatal (Shen and Abate-Shen, 2010, Kumar-Sinha and Chinnaiyan, 2003). In 
advance disease, the treatment regiments are usually based on androgen deprivation 
therapy which conducts to apoptosis of malignant tumor cells and reduction of tumor 
burden and/or circulating PSA levels. Nevertheless this is usually temporary, as in most 
cases tumor cells became resistant to this therapeutic option, and proliferate 
independently of androgens, which mechanism is still not fully elucidated (Kumar-Sinha 
and Chinnaiyan, 2003, Shen and Abate-Shen, 2010, Craft et al., 1999). 
 
 
Risk Factors 
Despite having a high prevalence and mortality, few data is certain about what 
causes this disease or even the best prevention strategy. In fact, there are several 
conditions that may compose a risk factor such as age, lifestyle, diet, African American 
race and familiar history of the disease or even genetic variants (Fowke et al., 2012, 
Shafique et al., 2012). Concerning age, which is the most significant risk factor, as its 
occurrence in patients aged below 50 is very low, with around 60% of all cases being 
registered in men over 70 years old (Macefield et al., 2009). Regarding familiar history, 
recently a novel HOXB13 G84E variant was associated with a significantly increased risk 
of hereditary PCa, however, it only accounts for a small fraction of all cases (Ewing et al., 
2012). About diet and lifestyle, it seems completely evident that dairy foods constitute one 
of the most solid predictor for PCa, interestingly at least 7 of 9 cohort studies and 12 of 14 
case-control studies observed a positive association between these two variables (Wolk, 
2005). Regarding African American men increased odd of developing PCa, it’s still a 
controversy issue as it’s not well defined whether it correlates with physiological or 
socioeconomic factors (Major et al., 2012). Still some authors describe an incidence rate 
of 233.8/100,000 for African Americans against 149.5/100,000 for Caucasians (Major et 
al., 2012). In fact, PCa prevention or disease prediction is still a delicate matter, which 
nowadays has its more solid bases on early detection by PSA screening, with all the 
controversy already referred. On the mean time, important clinical advances have been 
reported on prevention of this disease, as recently the Food and Drug Administration 
concluded that finasteride may reduce the risk of low-grade cancer but doesn’t have 
complete advantages when broad administrated (Theoret et al., 2011). Besides being a 
controversy issue, studies claim that obesity may constitute a risk factor for developing 
this disease or at least may influence the grade of PCa, and consequently its 
aggressiveness and prognosis (Fowke et al., 2012). Other interesting risk factor pointed 
by several studies is serum cholesterol levels, however it’s also still an inconclusive matter 
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that may be connected with grade and aggressiveness and consequently with mortality 
(Shafique et al., 2012). Also several chemicals and physic agents have been associated 
with PCa, such as dioxins, cigarette smoking, some farming pesticides, ultra violet 
radiation and minerals connected to occupational exposure (Mullins and Loeb, 2012), 
however none of them as achieved significant and solid arguments yet. 
 
 
Molecular Pathways of Carcinogenesis 
As previously mentioned, PCa is thought to be the end-product of the interplay of 
environmental, physiological and molecular/genetic factors. Age seems to be the common 
denominator of all those factors as several associations between gene expression 
alterations and age progression, including genes related to inflammation, oxidative stress, 
and cellular senescence, have been pointed (Shen and Abate-Shen, 2010). 
Concerning inflammation, its estimated that approximately a fifth of all human 
cancers including those of the stomach, liver and large intestine arise in a background of 
chronic inflammation (Haverkamp et al., 2008). Concerning PCa, the lack of solid 
epidemiologic and histological data connecting it with chronic inflammation, makes this 
correlation still unclear, although chronic prostatitis may be the origin of proliferative 
inflammatory atrophy (PIA), which is commonly seen in cancerous prostates and may 
constitute a precursor state, although this is still a controversial issue (De Marzo et al., 
1999). Recently, a study has proposed a link between PCa and sexually transmitted 
infectious agents like Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas 
vaginalis, Treponema pallidum, Human papilloma virus, Herpes simplex virus and Human 
herpes virus type 8, all of which have been detected in prostatic tissue (Wright et al., 
2012). That link was suggested by the observation that circumcision before the first sexual 
intercourse was associated with a 15% reduction in the relative risk of PCa (Wright et al., 
2012). Nevertheless, further studies are needed to clarify those findings. Another link 
between inflammation and PCa derives from the downregulation of a GSTP1, which 
encodes for an enzyme involved in the detoxification of reactive species, which are 
generated by inflammatory cells (Nakayama et al., 2004). Moreover, oxidative stress and 
consequent DNA damage may be due to hormonal deregulation, diet and/or epigenetic 
alterations (Shen and Abate-Shen, 2010, Gupta-Elera et al., 2012, Crawford et al., 2012). 
Indeed, oxidative stress may play a key role in cancer initiation and progression by 
regulating DNA function enhancers, cell cycle regulators, transcription factors (Gupta-
Elera et al., 2012) or by causing direct DNA damage, which may contribute to telomere 
shortening (Meeker et al., 2002). 
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In respect to genomic alterations, chromosomal rearrangements or copy numbers 
alterations are also involved in prostate carcinogenesis. The most commonly reported are 
the gains of 8q and losses of 3p, 8p, 10q, 13q and 17p (Dong, 2001, Lapointe et al., 
2004). Loss of chromosome 8p is considered a major genetic alteration in PCa initiation 
as it occurs in about 80% of all PCa and is already present in high grade prostatic 
intraepithelial neoplasia (HGPIN) lesions, which are putative PCa precursor lesions 
(Bergerheim et al., 1991). Several molecular pathways have also been linked with to PCa 
initiation and progression (Fig. 5). 
 
.  
Figure 5 – Progression pathways for human PCa and its connection to clinical stages. Adapted from (Shen 
and Abate-Shen, 2010) 
 
An important gene that may be lost during this process is NKX3.1 which is thought 
to play a significant role in prostate carcinogenesis (Abate-Shen and Shen, 2000), as it 
was found to be downregulated in HGPIN lesions (Bethel et al., 2006) as well as in 
advanced stage disease (Gurel et al., 2010). The function of NKX3.1 seems to be 
connected with the regulation of prostate epithelial differentiation and stem cell function 
(Bhatia-Gaur et al., 1999). 
MYC upregulation, usually associated with amplification (at 8q) has been 
recognized more than one decade ago (Jenkins et al., 1997) and may be present in 
HGPIN, suggesting a relevant contribution to PCa initiation and progression (Koh et al., 
2011). The protein encoded by MYC is a transcription factor which is vital in the control of 
the expression of genes involved in DNA replication, protein synthesis, cell cycle 
progression, cellular metabolism, chromatin structure, differentiation and stem cell 
differentiation (Koh et al., 2011). 
The tumor suppressor gene PTEN is frequently mutated or deleted in PCa 
(Salmena et al., 2008) and this alteration has been associated with advanced tumor 
stage, high Gleason grade, presence of lymph node metastasis, hormone refractory 
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disease, presence of ERG gene fusion and nuclear p53 accumulation (Krohn et al., 2012). 
The same study also found an association between PTEN’s deletion and PSA recurrence 
(Krohn et al., 2012), suggesting that this genetic alteration may constitute a promising 
biomarker for PCa diagnosis and/or prognosis. 
Several other genes have been reported to be involved in prostate carcinogenesis, 
including TP53, ZFHX3 , RB1 and APC (Grasso et al., 2012), implicated in several key 
pathways. Likewise, Akt/mTOR, mitogen-activated protein kinase (MAPK) or EGFR 
signaling deregulation , have also been linked to this malignancy (Grasso et al., 2012). 
A strong enrichment of ETS transcription factor target genes involved in protein 
synthesis, especially during the transition from benign epithelium to HGPIN lesion has 
been described (Tomlins et al., 2007). Although this pathway is initially upregulated, it 
seems to be downregulated during the transition from localized to hormone refractory 
metastatic PCa (Tomlins et al., 2007), owing to its central role in androgen signaling. 
Indeed, the same study revealed increased androgen signaling in HGPIN, compared to 
benign epithelium, but decreased androgen signaling in localized PCa when compared to 
HGPIN, as well as in high-Gleason grade cancer contrasted with low-grade, achieving the 
lowest expression levels in hormone refractory disease (Tomlins et al., 2007). 
The role of androgens is also pivotal in prostate carcinogenesis. Androgens bind to 
the human androgen receptor (AR), promoting a cascade of ligand-dependent and 
protein-protein interactions that may be connected with remodeling of chromatin structure 
at target promoters, recruitment of basal transcription machinery and RNA polimerase 
activation (Chmelar et al., 2007, Heinlein and Chang, 2004). However, the precise 
contribution of AR to prostate carcinogenesis and/or disease progression requires further 
clarification. 
Interestingly, the common fusion genes derived from ETS family members (e.g., 
ERG and ETV1) and the strong androgen-regulated TMPRSS2 are involved in prostate 
carcinogenesis owing to androgen induced expression (Hendriksen et al., 2006). The 
frequency of TMPRSS2-ERG fusion gene is 15% in HGPIN lesions and 50% in localized 
PCa, suggesting that this genetic alteration may occur after cancer initiation or at early 
stages of disease progression (Albadine et al., 2009, Mosquera et al., 2008). It may also 
function as a prognostic marker as some studies have indicated that it may be associated 
with clinical stage at diagnosis, although no correlation with clinical recurrence or mortality 
has been found (Pettersson et al., 2012).  
Finally, in addition to genetic mechanisms, epigenetic events, including microRNAs 
(miRNAs) deregulation, have been recognized as critical players in prostate 
carcinogenesis and their role will be addressed in the following sections (Shen and Abate-
Shen, 2010, van der Poel, 2007). 
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Epigenetics 
 
Epigenetics encompasses  DNA or proteins modifications which do not affect DNA 
sequence but regulate its expression, consequently altering the protein profile (Jeronimo 
and Henrique, 2011). In fact, the set of changes induced by this particular mechanisms 
are nowadays gaining significant clinical and pathological magnitude, being recognized as 
alternatives to gate-keeper genetic mutations or to chromosomal rearrangements 
(Jeronimo and Henrique, 2011). Whereas these genetic mechanisms are often 
irreversible, epigenetic mechanisms are dynamic and reversible, occurring as a response 
to events during embryogenesis or environmental factors and include biochemical 
modifications of histone proteins, DNA and expression deregulation of noncoding RNAs 
(Catto et al., 2011). 
Indeed, epigenetics may explain why the same genotipes can produce different 
phenotypes and it constitutes a documented base of some important events that occur in 
human cells, like the physiologic chromosome X inactivation in females (Heard et al., 
2004) or the clinical response to alkylating agents from gliomas depending on the 
methylation of the promoter region of MGMT (Esteller et al., 2000). Concerning human 
diseases, epigenetic alterations are increasingly being recognized as deeply implicated, in 
cancer but also in neurology, cardiovascular and autoimmune disorders (Fernandez et al., 
2012). For this purpose, the definition of the whole epigenome constitutes an important 
contribution, due to the development of powerful new genomic technologies (Fernandez et 
al., 2012). Regarding the former disease, there are strongly data supporting the role of 
epigenetic deregulation in malignant transformation and tumor progression, with several 
clinical applications such as potential biomarkers (Table 1) (Henrique and Jeronimo, 2004, 
Esteller, 2011, Phe et al., 2010). 
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Table 1 – Genes that are frequently methylated in PCa and their potential role as a biomarker. Adapted 
from (Phe et al., 2010) 
Gene Name 
Sensitivity 
(%) 
Specificity 
(%) 
GSTP-1 Glutathione S-transferase P1 33–90 84.6–100 
CDKN2A Cyclin-dependent kinase inhibitor 2 A (p1 30–72  
CCND2 Cyclin D2 32  
p14b  9.5  
MGMT O-6-methylguanine DNA methyltransferase 25–75  
ASC 
Apoptosis-associated Speck-like protein 
containing a CARD 
37  
AR Androgen receptor 8–28  
ESR1 Oestrogen receptor 1 80–95  
ESR2 Oestrogen receptor 2 79–100  
RARβ Retinoic acid receptor β 68–95 65.4–96.9 
EDNRB Endothelin receptor type B 15–100 11.5 
RASSF1A 
Ras association domain family protein 1 
isoform A 
54–96  
MDR1 Multidrug resistance receptor 1 50.8–100 69.2 
CDH13 Cadherin 13 45–53.6  
APC Familial adenomatous polyposis 27–100 50–100 
TIMP3 TIMP metallopeptidase inhibitor 3 4  
CDH1 E-cadherin 21–54  
CD44  19–77  
T1G1  41.9–96.3 88.5 
LAMA 3 α-3 laminin 44  
LAM B3 Β-3 laminin 18  
LAM C2 γ-3 laminin 41  
SCAV 1 Caveolin 1 90  
PTGS2 Prostaglandin endoperoxide synt 65.4–88 84.6–100 
RUNX3 Runt-related transcription factor 44  
WIF1 WNT inhibitory factor 1 28  
COX-2 Cyclo-oxygenase 2  78 
 
 
 
DNA Methylation 
This epigenetic regulation mechanism is definitely the most studied and relies on 
the activity of DNA methyltransferases (DNMTs) such as DNMT3L together with either 
DNMT3A or DNMT3B or by a replicative maintenance procedure that is operated by 
UHRF1 coupled with DNMT1 (Scholz and Marschalek, 2012). This complex uses S-
adenosyl-methionine as the methyl donor to give rise to 5-methylcytosine, by adding 
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methyl groups to the fifth carbon position of a DNA cytosine after replication (Jeronimo 
and Henrique, 2011, Goldberg et al., 2007). In fact, nearly all DNA methylation occurs on 
cytosine residues, located side by side to guanine nucleotides, forming cytosine-
phosphate-guanine (CpG) dinucleotides, which usually appear heavily repeated in 
genomic sequences called CpG islands (Goldberg et al., 2007, Jeronimo and Henrique, 
2011). Usually these regions are preferably found in 5’ ends, like promoters untranslated 
regions or exon 1 of human genes and their methylation might prevent gene expression 
(Jeronimo and Henrique, 2011, Goldberg et al., 2007). There are other genomic regions 
affected by DNA methylation, located nearby CpG islands, but with less CpG 
dinucleotides, termed CpG shores, indeed this regions may also regulate gene expression 
(Dudziec et al., 2011, Jeronimo and Henrique, 2011). Not only abnormal methylation may 
occur, but also demethylation might take place, promoting inappropriate transcription of 
genes. This process is mediated by the action of TET family proteins or by GADD45 
family members (Scholz and Marschalek, 2012). In fact, some regions, especially those 
located near the centrosome, transposons, and inserted viral sequences are 
physiologically methylated, in order to maintain genomic reliability, preventing incorrect 
recombination events that may lead to genetic errors, such as gene disruption, 
translocations and chromosomal instability (Jeronimo and Henrique, 2011). DNA 
methylation may prevent expression either directly through transcriptional activators’ 
obstruction or indirectly by recruitment of methylcytosine-binding proteins (Jeronimo and 
Henrique, 2011). Indeed, these may promote the enrolment of DNMTs and histone 
deacetylases (HDAC), which may result in chromatin alterations, repressing transcription 
(Jeronimo and Henrique, 2011). 
Interestingly, in cancer, these methylation patterns are often altered whereas the 
promoter region of tumor suppressor genes becomes hypermethylated (Fig. 7) or 
oncogenes undergo hypomethylation (Jeronimo and Henrique, 2011, Lopez-Serra and 
Esteller, 2008). Hence, these alterations in methylation patterns of gene promoters, 
whose mechanism and cause are still unknown, might have an impact  in expression of 
several cancer-related genes such as the tumor supressores p16, INK4a, TP53, hMLH1, 
PTEN and BRCA1 and the oncogenes KRAS, BRAF and PIK3CA (Lopez-Serra and 
Esteller, 2008, Kwon and Shin, 2011). 
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Figure 7 – DNA methylation in normal and cancer cells. A hypomethylated promoter allows normal gene 
expression while DNA hypermethylation leads to gene silencing. In cancer cells aberrant hypermethylation may 
promote tumorgenesis. This process is catalyzed by the DNA methyltransferases (DNMTs), by adding a methyl group 
(CH3) to the 5-position of the cytosine of the CpG dinucleotides (black circles, methylated sites; white circles, 
unmethylated sites). Adapted from (Li and Tollefsbol, 2010) 
 
There are several drugs that may hamper DNA methylation, one of the most well 
studied  is 5-Aza-2'-Deoxycytidine (5-AZA-DC) (Fig. 8), which was first synthesized 40 
years ago (Christman, 2002). In fact, regardless of having an anti-metabolic activity, it is 
incorporated in DNA inhibiting DNMTs activity (Christman, 2002). This compound is 
currently used in in vitro assays in order to verify the role of genes promoter methylation 
and specific gene´s expression (Christman, 2002). 
 
 
 
 
 
 
 
Figure 8 – Chemical structure of 5-Aza-2'-Deoxycytidine. Adapted from (Yang et al., 2012) 
 
Interestingly, in PCa, epigenetic alterations, specifically DNA aberrant methylation, 
are highly prevalent and occur early in carcinogenesis. Indeed, more than 50 genes 
involved in key cellular pathways (DNA repair and damage prevention, signal 
transduction, cell hormone response, cycle control and apoptosis, tumor invasion and 
architecture, have been commonly found to be hypermethylated (Table 2) (Henrique and 
Jeronimo, 2004). One of note is GSTP1, which may allow the detection of 80-90% of 
prostate adenocarcinomas with perfect specificity (Henrique and Jeronimo, 2004). 
Nonetheless, further studies are needed to elucidate how and why this aberrant 
methylation takes place. 
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Table 2 – Frequency (%) of hypermethylation in several cancer-related genes in prostate tissue. Adapted 
from (Henrique and Jeronimo, 2004) 
Gene NPT HGPIN PCa 
APC 6% - 27% 
AR 0-11% 5% 8-15% 
CD44 - - 32-67% 
CDH1 25% - 0-54% 
CDH13 16% - 31% 
CRBP1 0-2.8% 8.6% 47.2% 
Cyclin D2 6% - 32% 
DAPK 7-11% 0% 1-36% 
EDNRB 83-91% - 83% 
ER (α-A, α-C, β) 0% - 79-95% 
FHIT 0% - 15% 
GSTP1 0-29% 30-70% 36-94% 
HIC-1 83-90% 100% 99% 
MGMT 0-3% 10% 0-2% 
p16 0% - 3-13% 
PR (A, B) 0% - 0 
RARβ2 3-23.3% 20-94% 53-97.5% 
RASSF1A 16% - 53-71% 
TIMP-3 6-7% 5% 6% 
Abbreviations: NPT- Morphologically Normal Prostate Tissue;  
HGPIN- High Grade Prostatic Intraepithelial Neoplasia; PCa- Prostate Cancer  
 
 
Histone Modifications and Chromatin Remodeling 
Chromatin is the higher order of organization of genomic information. Nucleosome 
constitutes it’s basic unit, which is composed by a histone octamic protein core, around 
which 147 bp of DNA are wrap up (Loizou et al., 2006). These dynamic structures provide 
not only a physical support to DNA, but also participate in transcriptional regulation, repair 
and replication (Jeronimo and Henrique, 2011). Indeed, the N-terminal ‘tails’ of these 
structures may be target of several enzymes (kinases, acetytransferases or 
methyltransferases) that using cellular metabolites, such as phosphate, acetyl, or methyl 
groups promote their phosphorylation, acetylation, and methylation, which may alter gene 
expression. (Katada et al., 2012, Jeronimo and Henrique, 2011). Globally, these 
chromatin modifying/remodeling activities constitute normal and physiological 
mechanisms use by normal cells to process DNA breaks repair and to defend themselves 
against genomic integrity aggressions (Loizou et al., 2006). In fact, the most well 
elucidated mechanisms are acetylation which reduces histones affinity for DNA and allow 
chromatin extension and openness, favoring gene transcription and the other one is 
histone methylation which may inhibit gene transcription by the opposed mechanism, 
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depending on which aminoacids are methylated and DNA methylation itself (Fig. 9) 
(Jeronimo and Henrique, 2011). Concerning PCa, histone modifications, nucleosomal 
remodeling and chromosomal looping may constitute important epigenetic mechanisms 
that regulate gene expression. For example the alteration in the repressive histone mark 
H3K27me3 and the increased expression of H3K27me3 methyltransferase EZH2 
conducts to the silencing of tumor suppressor genes (for example GAS2 and ADRB2) 
(Chen et al., 2010). On the other hand, both the genomic position alteration and protein 
expression of active histone mark H3K4 methylation may contribute to activation of proto-
oncogenes (for example UBE2C) in this neoplasia (Chen et al., 2010). Nucleosome 
repositioning is not only related to the silencing of tumor suppressor genes, such as 
MLH1, but is also connected to the activation of genes involved in PCa progression (PSA 
and TMPRSS2) (Chen et al., 2010). It is also thought that AR gene regulation may have a 
strong influence of chromatin remodeling or histone modification (Chen et al., 2010). 
 
 
Figure 9 – Active transcription is associated with hyperacetylation of histones by the adding of an acetyl 
group to specific lysines residing within the N terminal region of histones. Thus, the affinity of histones for DNA is 
reduced, conducting to and open chromatin conformation which allows transcription factors and RNA polymerase 
contact with the promoter region of a certain gene. Also, the demethylation of certain lysines on histones (H3K4, 
H3K36, and H3K79) located on the promoter regions also induces transcription. On the other hand methylation and 
hypoacetilation of certain other lisines on histones (H3K9, H3K27, and H4K20 residues) may regulate gene expression 
repression. These modifications are catalyzed by a few chromatin-modifying enzymes such as DNA 
methyltransferases (DNMTs), histone deacetylases (HDACs), histone methyltransferases (HMTs), and histone 
demethylases (HDMs). As a result, inactive genes may be upregulated when the cell is exposed to DNMT-inhibitors 
and HDAC inhibitors. Adapted from (Mascarenhas et al., 2011) 
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Non-conding RNAs 
Recent evidence indicate that non-coding RNAs may play an important role in 
controlling multiple genetic and epigenetic phenomena’s with a significant impact in 
normal cellular differentiation and organism development (Goldberg et al., 2007, Mattick 
and Gagen, 2001). Interestingly in mammals, noncoding RNAs are closely involved in 
dosage compensation, such as changes in chromatin structure induced by histone 
modifications (Bernstein and Allis, 2005).  
There are two major groups of non-coding RNAs, the small ncRNAs and the long 
ncRNAs (Hassler and Egger, 2012). Thus, small ncRNAs derive from longer precursors 
and include transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), microRNAs (miRNAs), piwi 
interacting RNAs (piRNAs), small nuclear RNAs (snoRNAs) and other less characterized 
RNAs (Hassler and Egger, 2012). Conversely, long ncRNAs constitute a heterogeneous 
class of mRNA-like transcripts, yet non-coding, with 200 bp to 100 kb. 
There is still much to be elucidated about the mechanisms by which these 
interference RNAs regulate gene expression and its relation with cancer. These questions 
will be target of further discussion. 
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MicroRNAs 
 
MicroRNAs are small (~22 nucleotides), single-stranded,  non-coding untranslated 
RNAs that control gene expression acting post-transcriptionally by destabilization or 
translational repression of the messenger RNA (mRNA), inhibiting protein synthesis 
(Ostling et al., 2011, Choudhry and Catto, 2011). Specifically, the 5’ end of a miRNA 
(positions 2–8 nt) binds to a targeting sequence, located at the 3’ end of the mRNA- 3’ 
UTR region- depending on the level of complementary between the two sequences (Catto 
et al., 2011, Betel et al., 2008). Nevertheless, most miRNAs induce a modest reduction 
(less than two-fold) in their target concentration (Bartel, 2009). In a historical perspective, 
miRNAs were first described in a work with Caenorhabditis elegans, where two regulatory 
RNA sequences where reported – lin-4 and let-7 – lately these regulatory sequences 
where also described in other species, including in humans (Bartel, 2009). Currently over 
1,223 human miRNAs mature sequences have been reported in the 
http://www.mirbase.org base catalog (Mestdagh et al., 2012). The miRNAs are expressed 
from independent transcription units, because they do not contain an open reading frame 
and are expressed separately from the nearby genes (Lau et al., 2001). Their expression 
profile varies between species and in each specie during embryogenesis, suggesting that 
miRNA might be connected to both gene and protein expression and consequently to the 
regulation of a variety of pathways (Lau et al., 2001).  
 
 
The Biogenesis of MiRNAs  
Presently it is accepted that within the nucleus, miRNAs are transcribed by a 
polymerase II into a long primary transcripts (pri-miRNAs) which contain both 5’-cap 
structure (7MGpppG), as well as a 3’-end poly(A) tail, with about 70 nucleotides length 
(Takada and Asahara, 2012, Iorio and Croce, 2012). Then, miRNAs fold back on 
themselves to form distinctive hairpin-shaped pre-miRNAs by the action of nuclear RNase 
III Drosha (Kim, 2005), associated to a double stranded RNA-binding protein DGCR8, 
known as the microprocessor complex (Iorio and Croce, 2012, Carthew and Sontheimer, 
2009). Alternatively, but less frequent, miRNA processing might occur through splicing of 
pri-miRNA transcripts to release introns which are structurally identical to pre-miRNAs 
(Carthew and Sontheimer, 2009). Following this nuclear processing, the pre-miRNAs are 
exported to the cytoplasm, where its maturation and action will take place, this transport is 
made via one of the nuclear Ran-GTP-dependent transport receptors exportin-5 (Kim, 
2005, Iorio and Croce, 2012). Here in, a RNAse III enzyme Dicer, processes pre-miRNAs 
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into ~22-nucleotide miRNA duplexes (Kim, 2005). Indeed, the PAZ domains of Dicer are 
crucial to this process, as they interact with the 3’ overhang and determines the cleavage 
site in a ruler-like fashion (Carthew and Sontheimer, 2009).  The maturation process is 
finalized by the cleavage of a precursor miRNA hairpin, into a transitory miRNA/miRNA* 
duplex, which includes a mature miRNA with a biological activity and a complementary 
strand (identified by adding a *) usually subject to degradation (Iorio and Croce, 2012), 
(Bhayani et al., 2012, Griffiths-Jones, 2004).  
These mature miRNAs are ready to regulate a variety of pathways, by interfering 
with the translation process of certain mRNAs. This process requires an incorporation of 
the miRNA mature sequence into miRNA-containing ribonucleoprotein complex, also 
called as mirgonaute ou miRISC (miRNA-containing RNA-induced silencing complex) 
(Kim, 2005), which contains AGO proteins and binds to target mRNA (Iorio and Croce, 
2012). The whole miRNAs biogenesis and function process is illustrated on figure 10.                               
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – After synthesis, mature miRNA is incorporated into an RNA-induced silencing complex with 
Argonaut proteins. This complex targets mRNA through the miRNA seed region, inducing either complete mRNA 
degradation (by perfect annealing, as seen in plants) or alterations in translation (with imperfect miRNA/mRNA 
annealing, as seen in mammals). Adapted from (Catto et al., 2011) 
 
Target binding is made by complementarily, into the 3’ untranslated regions (UTR) 
of the target transcripted gene (Iorio and Croce, 2012, Ostling et al., 2011). In fact, as 
referred, this target interaction does not require complete complementarily between the 
two sequences, however near perfect base-pairing of the 5’ region of the miRNA seems to 
be determinant in target recognition (Betel et al., 2008). Remarkably, each miRNA might 
control hundreds of target genes and may modulate up to 60% of all transcripts (Ostling et 
al., 2011), accounting itself for ~1% of the genome (Kim, 2005). The main target of each 
miRNA and exactly how its regulation is performed, is still a matter study, however the 
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reduction of the target gene expression appears to occur by initiation of translation 
inhibition or by degradation of the target mRNA (Betel et al., 2008). Concerning this issue, 
there are several databases that provide miRNA target predictions based on complex 
mathematic algorithms and several criteria such as: sequence complementarily to target 
sites or calculations of mRNA secondary structure and energetically favorable binding 
between sequences (Betel et al., 2008). 
 
 
MiRNAs and Cancer 
MiRNAs have also been implicated in cancer, ever since a study revealed that the 
gene cluster containing the miR-15 and miR-16 was deleted in most patients with chronic 
lymphocytic leukaemia (Calin et al., 2002). These miRNAs were later described as acting 
as tumor suppressing genes by targeting the oncogene BCL2, then interfering with cell 
survival and apoptosis (Cimmino et al., 2005). Moreover, subsequent reports revealed 
that miRNAs expression are altered in many cancers and have been implicated in 
tumorigenesis (Catto et al., 2011). MiR-21 constitutes a good  example of an oncogenic 
miRNA that is frequently overexpressed in several tumors, such as breast, colorectal, 
lung, and pancreatic cancer, as well as, in glioblastomas, neuroblastomas, leukemia and 
lymphomas (Catto et al., 2011, Kong et al., 2012). Indeed, miRNAs expression constitutes 
an important mechanism of regulation of several cancer-related genes, relevant for 
apoptosis avoidance, cell proliferation control, epithelial-to-mesenchymal transition and 
angiogenic signaling. Furthermore, the potential role of miRNAs as tumor biomarkers is 
being explored in several cancers. 
 
 
Mechanisms of MiRNAs Deregulation in Cancer 
Interestingly, miRNA may be targeted by several genetic alterations. In fact, nearly 
50% of the known miRNAs are located inside or nearby fragile sites and minimal regions 
of loss of heterozigosity, minimal zones of amplification and common breakpoints which 
have been already linked to cancer (Kozaki and Inazawa, 2012). Additionally, mutations or 
polymorphisms on the interference binding site of mRNA coding oncogenes may 
increasing cancer risk, as described to happen in non-small-cell lung cancer for KRAS 
(Chin et al., 2008). In addition, several reports verified that most miRNAs have lower 
expressions in tumors compared to normal tissues, indicating that they may function 
typically as tumor suppressors (Lu et al., 2005, Agirre et al., 2009, Creighton et al., 2010). 
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Thus, miRNAs may be targeted by mutations themselves or amplification or methylation 
events, becoming over or underexpressed (Fig.11). 
 
 
Figure 11 – miRNAs may regulate tumorgenesis at different levels. Oncogenic miRNAs upregulation may 
reduce expression of tumor-suppressor proteins, contrarily to the downregulation of tumor-suppressing miRNAs, 
which may increase oncogenic protein levels. Mutations in tumor-suppressing miRNAs and/or on its mRNA binding 
sites can cause tumorgenesis, on the other hand mutations in oncogenic miRNAs or targets would reduce 
tumorgenesis. Adapted from (Kong et al., 2012) 
 
Importantly, some studies in recent years correlate miRNAs profile with disease 
outcome or response to therapy (Calin et al., 2002, Yanaihara et al., 2006). For example, 
after a median follow-up time of 50 months, miR-96 downregulation was associated with 
cancer recurrence after surgery (Schaefer et al., 2010). Indeed, miRNA profiles may 
become a useful tool in assessing clinical stage, as a study using a metastatic versus a 
non-metastatic PCa xenograft line, found that 140 miRNAs were differently expressed, 
including miR-16, miR-34a, miR-145 and miR-205 (Watahiki et al., 2011). Owing to the 
fact that miRNA may also be detected in body fluids, mostly serum and plasma but also in 
urine samples, they might also serve as biomarkers for early detection, as proposed for 
miR-141 and miR-375 (Kuner et al., 2012). 
Concerning PCa, its first described miRNA profile was reported by Porkka et al. 
(Porkka et al., 2007), in which the authors have identified 51 miRNAs (37 downregulated 
and 14 upregulated) that were differentially expressed in PCa when compared with benign 
prostatic lesions. These results were further confirmed by several studies in which a 
higher frequency of downregulated miRNAs has been reported in PCa, versus to the 
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lower percentages of miRNAs found to be upregulated in the same malignancy (Schaefer 
et al., 2010, Catto et al., 2011) (Table 3).  
In fact, some miRNAS have already been widely described as being 
downregulated, specifically miR-145, which has been implicated on apoptosis by 
regulating TNFSF10, a pro-apoptotic gene, as its reconstitution induced cellular death 
(Zaman et al., 2010) and/or regulating FSCN1 gene which is related to cell growth, 
migration and invasion (McLaughlin et al., 2005). Other miRNA that has received wide 
attention is miR-205, indeed this miRNA seems to be downregulated in PCa and seems to 
be connected to apoptosis escape by possibly targeting Bcl-w, promoting pharmacologic 
treatment resistance (Bhatnagar et al., 2010). 
 
Table 3 – A summary of miRNAs with altered expression in PCa, including their targeted mRNAs and 
pathways. Adapted from (Catto et al., 2011) 
 
MiRNA Expression MRNA target Pathway 
miR-20a Up E2F1-3 Apoptosis 
miR-21 Up PTEN, AKT, androgen pathway Apoptosis, mTOR pathway, androgen 
independence 
miR-24 Up FAF1 Apoptosis 
miR-32 Up BCL2L11 (Bim) Apoptosis 
miR-106b Up P21, E2F1 Cell cycle control/apoptosis and 
proliferation 
miR-125b Up P53, BBC3 (Puma), BAK1 Apoptosis 
miR-148a Up CAND1 Cell cycle control 
miR-221 Up p27 (kip1) Cell cycle control and androgen 
independence 
miR-222 Up p27 (kip1) Cell cycle control and androgen 
independence 
miR-521 Up Cockayne syndrome protein A DNA repair 
miR-1 Down Exportin-6, tyrosine kinase 9 Gene expression 
miR-7 Down ERBB-2 (EGFR, HER2) Signal transduction 
miR-15a-16 
cluster 
Down CCND1 and WNT3a Cell cycle regulation, apoptosis and 
proliferation 
miR-34a Down HuR/Bcl2/SIRT1- >p53/p21/BBC3 Apoptosis and drug resistance 
miR-34c Down E2F3, bcl2 Apoptosis and proliferation 
miR-101 Down EZH2 Gene expression 
miR-107 Down Granulin Proliferation 
miR-143 Down MYO6, ERK5 Cell migration, proliferation 
miR-145 Down MYO6, BNIP3L->AIFM1, CCNA2, 
TNFSF10 
Cell migration, apoptosis, cell cycle 
control 
miR-146a Down ROCK1 – 
miR-148a Down MSK1 Proliferation, stress response and drug 
resistance 
miR-205 Down IL-24 and IL-32, Cepsilon Cell growth and invasion, EMT 
miR-331-3P Down ERBB-2, CDCA5, KIF23 Signal transduction, cell cycle control 
miR-449a Down HDAC-1 Gene expression 
miR-1296 Down MCM family DNA replication 
Let-7a Down E2F2 and CCND2 Cell cycle control and proliferation 
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Recently, miR-130a, miR-205 and miR-203 have been implicated in androgen 
receptor and MAPK pathways, however the molecular mechanism causing this 
downregulation have not, yet, been found (Boll et al., 2012). 
Similar to protein coding genes, one reliable explanation for miRNAs’ 
downregulation might be the aberrant methylation of their respective codifying genes. 
Indeed 13 to 28% of human miRNA genes are located within 3 and 10 kb from a CpG 
island, respectively (Choudhry and Catto, 2011). In addition, it has been suggested that 
81.9% of predicted promoters of intergenic miRNA genes contain at least one CpG island 
(Wang et al., 2010). On the other hand, concerning intragenetic miRNAs, approximately 
13.0% have been reported to be located within 500 bp downstream of a CpG island 
(Wang et al., 2010). However, due to the fact that the location of the promoter region of 
miRNAs codifing genes is not fully clarified this is still a controversial issue.  
Remarkably, tumor suppressor miRNAs’ regulation by hypermethylation, has been 
suggested since the re-expression of miR-9-1 and miR-127 was achieved after the 
exposure of human cancer cell lines to 5-AZA-DC (Lehmann et al., 2008) (Saito et al., 
2006) (the mechanistic of these studies is elucidated in Figure 12).  
 
 
 
 
 
 
 
Figure 12 – Activation of coding or non-coding genes that might function as tumor suppressors using an 
epigenetic therapy with DNMT and/or HDAC inhibitors. The activation of tumor suppressor miRNAs may cause 
downregulation of target oncogenes. Adapted from (Saito and Jones, 2006) 
 
Concerning PCa, miR-145, miR-205, miR-132, miR-126 and miR-193b have been 
recently reported to be regulated through methylation (Rauhala et al., 2010, Suh et al., 
2011, Saito et al., 2009, Bhatnagar et al., 2010, Formosa et al., 2012). However, most of 
these studies were only performed in cell lines or in a limited number of primary tumors. 
Thus, epigenetic regulation of miRNA expression is still a largely unexplored field of 
research in PCa. 
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AIMS OF THE STUDY 
 
The key objective of this Master Thesis, performed at the Cancer Epigenetics 
Group of the Research Center of the Portuguese Oncology Institute – Porto, was to 
identify new epigenetically downregulated miRNAs in PCa, using an expression profiling 
based approach. Furthermore, it was our purpose to validate these miRNAs in a larger set 
of clinical samples, in order to identify a putative tumor biomarker amenable to be used for 
diagnosis and prognostic assessment of this malignancy. 
The specific aims of this project were: 
1. Identify miRNAs that are downregulated in PCa compared to normal prostatic 
tissues (NPT); 
2. Identify miRNAs that are upregulated in prostate cancer cell lines exposed to 
demethylating agents compared to untreated cell lines; 
3. Validate the miRNAs putatively regulated by methylation by quantitative 
methylation-specific PCR in a larger series of tumors; 
4. Assess the methylation status of the identified miRNAs in prostatic pre-malignant 
lesions (HGPIN); 
5. Evaluate the performance of the newly identified miRNAs as tumor biomarkers in 
clinical samples. 
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METHODOLOGIES 
 
Clinical Samples 
Patients and Tissue Sample Collection 
A total of 105 men with clinically localized PCa, diagnosed and primarily submitted 
to radical prostatectomy in I.P.O.F.G – Porto, from 2002 and 2006, were included in this 
study [stage T1c and T2, according to TNM system (Hermanek et al., 1997)]. Of the total 
105 PCa tissues available, 10 were randomly selected to perform the global miRNA 
expression, while 101 were used for individual validation studies. HGPIN lesions were 
identified in 56 cases and also collected for further analysis. As sample controls, 14 
morphologically NPT specimens were collected from the peripheral zone of prostates that 
did not harbor PCa obtained from cystoprostatectomy specimens of bladder cancer 
patients. The 4 NPT used were also randomly chosen from the 14 available patients 
tissues, to assess the global miRNA expression. All specimens were frozen at -80ºC and 
then cut with a cryostat for microscopic evaluation and selection of potential areas for 
analysis. Cut sections were trimmed to maximize target cell content (>70%) and then DNA 
extraction was performed using phenol-chloroform. From each specimen, parallel 
fragments were collected, formalin treated and paraffin-embedded for histopathological 
examination. Gleason’s score (Gleason and Mellinger, 1974) and pathological staging 
(Hermanek et al., 1997) were evaluated by an expert pathologist (Rui Henrique, M.D., 
PhD). Relevant clinical data was collected from the clinical charts.  
 
 
Urine Sample Collection and Processing 
Morning voided urine samples (one per patient) were collected from 39 patients 
with PCa diagnosed and treated at the in I.P.O.F.G – Porto, Portugal. 15 male controls 
were randomly chosen among healthy donors (HD) with no personal or family history of 
cancer. Patients and controls were enrolled after informed consent. Urine storage and 
processing conditions were standardized: each sample was immediately centrifuged at 
4000 rpm for 10 minutes; the pelleted urine sediment was then washed twice with 
phosphate-buffered saline, and stored at -80ºC. 
 
These studies were approved by the institutional review board (Comissão de Ética) 
of Portuguese Oncology Institute - Porto, Portugal. 
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Cell Culture and Treatment with 5-Aza-2'-Deoxycytidine 
In order to identify miRNAs putatively regulated by methylation, representative 
PCa cell lines were selected and exposed to an epigenetic modulating drug, namely 5-
Aza-2'-Deoxycytidine (5-AZA-DC). 
PCa cell lines VCaP (positive for the TMPRSS2-ERG fusion gene), PC-3 
(androgen independent) and LNCaP (androgen dependent) (American Type Culture 
Collection, MD, USA) were grown in recommended medium, supplemented with 10% fetal 
bovine serum (Gibco, Invitrogen, Carlsbad, CA) and antibiotics (100 units/mL of penicillin 
G and 100 mg/mL of streptomycin; Gibco, Invitrogen, Carlsbad, CA), in a humidified 
atmosphere of 5% CO2 at 37Cº, according to instructions. These three cell lines were 
kindly provided by Prof. Ragnhild A. Lothe from the Department of Cancer Prevention at 
The Institute for Cancer Research, Oslo, Norway. Cells were grown to 20 to 30% of 
confluence in 175 cm3 flasks and then submitted to demethylation treatment with 1M of 
5-AZA-DC (Sigma-Aldrich®, Germany) for 72h. As controls, same cell lines were left 
untreated for 72 hours, only with medium exchange (Mock Samples). Culture medium 
and/or the appropriate drug were changed every day, always in the same amount and 
concentration and all treatments/mocks were made in triplicate. Cells were trypsinized and 
harvested after period completion and centrifuged. After being washed with PBS 1x, cells 
were frozen at -80ºC until DNA and RNA extraction, separately. To prepare the stock 
solution at a concentration of 100 mM of 5-AZA-DC, 10 mg of the compound were 
dissolved in 438 µL of 50% of acetic acid and stored at -80ºC. Prior to being added to cell 
culture, 5-AZA-DC solution was diluted in PBS 1x to a final concentration of 10 mM. This 
solution was stored at -20ºC during the using period. 
 
 
Gene Expression Analysis 
 
Global microRNA Expression 
In order to determine which miRNAs were differentially expressed between NPT 
against PCa and which of these might be epigenetically regulated by comparing the 5-
AZA-DC treated cells against the untreated cell lines, a qRT-PCR miRNA Plates 
expression profiling was performed. In a total of 20 samples (10 PCa, 4 NPT, and the 3 
PCa cell lines mock and exposed to 5-AZA-DC were run in parallel using the miRCURY 
LNA™ Universal RT microRNA PCR system kit from Exiqon® (Vedbaek, Denmark), which 
has been previously reported by others (Koo et al., 2012, Jorde et al., 2012).  
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Using this approach, for each sample, the expression of 740 miRNAs (distributed 
by two 384 well plates) was measured by the Roche Real-Time PCR System [Light Cycler 
480 instrument (Roche, Basel, Switzerland)], following the recommended protocol (Exiqon 
miRCURY LNA™ Universal RT microRNA PCR, Protocol B – Human and Mouse&Rat 
microRNA PCR Panels).  
Amplification reactions were performed in a 384 well plate containing in each well 
lyophilised primers specific for the chosen miRNA, and consisted of 10 µL of a mixture 
containing  20 µL of the cDNA previously synthesized, 1980 µL of deionized nuclease free 
water, and 2000 µL of SYBR® Green master mix.   
Real-time PCR reactions (Fig.13) were carried out at 95°C for 10 minutes, followed 
by 45 amplification cycles at 95°C for 10 seconds and 60°C for 1 minute with ramp-rate 
1.6ºC/s6 optical read (Fig. 14). 
Each plate also contained, 3 interplate calibrators, 2 water blanks, 3 empty wells 
and 6 reference genes (SNORD38B, U6, SNORD49A, miR-191, miR-423-5p, miR-103) 
suggested by the kit  manufactures and which some were already proposed as universal 
reference miRNAs like miR-191 and miR-103 (Mestdagh et al., 2009).  
 
 
 
 
 
Figure 13 – The cDNA template is then amplified using microRNA-specific and LNA™-enhanced forward and 
reverse primers (step A). SYBR® Green was used for sequences detection (step B). Adapted from miRCURY LNA™ 
Universal RT microRNA PCR, Instruction manual Version 4.1 #203300 (August 2011) 
 
The expression for each miRNA is given by the difference between its Ct value and 
the average Ct value of reference genes, per sample, within a given sample set 
(Mestdagh et al., 2009). Then, the data was analyzed using the comparative Ct method 
(Schmittgen and Livak, 2008). 
 The fold variation of the expression levels were determined by 2-ΔCT to prostate 
tissues: Prostate tissue ΔCT=CTmiRNA of interest – average CT of reference genes. In 
cell lines the fold change due to treatment levels were calculated by 2-ΔΔCT (ΔΔCT=ΔCt 
treated cells - ΔCt mock cells). The final results were generated by a log2 transformation 
of the real-time PCR data presented as 2-ΔCT or 2-ΔΔCT. Additionally, a fold variation 
value <-1.0 represents a downregulated miRNA, whereas a fold variation value >1 
corresponds to an upregulated miRNA.  
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Figure 14 – Illustrative qRT-PCR amplification, with evidence to the baseline interval (happens before the 
amplification takes off) and the threshold above background. Adapted from miRCURY LNA™ Universal RT microRNA 
PCR, Instruction manual Version 4.1 #203300 (August 2011) 
 
MiRNAs upregulated in more than 1.0-fold after 5-AZA-DC treatment in at least 
two of three PCa cell lines and simultaneously downregulated in tumor samples compared 
with normal tissue were considered to be potential targets for further methylation studies. 
Finally, all selected miRNAs were confirmed to be expressed in Prostatic tissue using a 
publically available database (www.microrna.org). 
 
Quantitative Gene Expression Validation 
The miRNAs identified by miRCURY LNA™ Universal RT microRNA PCR system 
kit were further confirmed by quantitative reverse-transcriptase (qRT-PCR) expression 
analysis. 
 
 
RNA Extraction 
Total RNA was extracted from all 105 PCa samples, three cell lines treated and 
untreated and from the 14 NPT samples, using PureLink™ RNA Mini Kit (Invitrogen, 
Carlsbad, CA, USA), according to manufacturer’s instructions. RNA concentrations were 
determined using a ND-1000 Nanodrop (NanoDrop Technologies, Wilmington, USA) and 
the RNA quality was verified by an electrophoresis in agarose gel. 
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cDNA Synthesis 
Total cDNA was obtained from total RNA. In brief, the RNA was tailed with a 
poly(A) sequence at its 3’end and then reverse transcribed to cDNA using a universal 
poly(T) primer with a 3’end degenerate anchor and a 5’end universal tag (Fig.15). 
 
 
 
 
 
 
 
Figure 15 – A poly-A tail is added to the mature microRNA template (step A). cDNA is synthesized using a 
poly-T primer with a 3’ degenerate anchor and a 5’ universal tag (step B). Adapted from miRCURY LNA™ Universal RT 
microRNA PCR, Instruction manual Version 4.1 #203300 (August 2011) 
 
For each sample, 20 ng of total RNA was reverse transcribed into cDNA using the 
standard protocol of miRCURY LNA™ Universal RT microRNA PCR (Exiqon®, Vedbaek, 
Denmark). The following components were added to an RNAse-free PCR tube on ice: 4 
µL of a previously diluted at 5 ng/µL RNA solution, 4 µL of a 5x Reaction buffer (includes 
universal reverse transcription primers), 9 µL of nuclease-free water, 2 µL of enzyme mix 
and 1 µL of RNA spike in, previously re-suspended. Final mix reaction was incubated for 
60 minutes at 42ºC, followed by 5 minutes at 95% for reverse transcriptase inhibition, 
using a Veriti® Thermal Cycler (Applied Biosystems, Foster City, CA, USA). Final 
products were stored at -20ºC according to manufactures’ instructions. 
 
 
Quantitative Reverse-Transcriptase PCR (qRT-PCR) 
Thus, for individual assays, the cDNA from the 101 tissue samples which was 
previously synthesized, was freshly diluted 80x (395  µl to each 5  µl of cDNA) in nuclease 
free water (MP Biomedicals, LLC, OH, USA) in low-nucleic acid binding tubes and then 4 
μl of this solution was added in a 96 well plate, to a previously prepared solution 
containing 0.2 µL of a passive ROX reference dye (Invitrogen, Carlsbad, CA, USA), 1 µL 
of miRNAs primers, specific to a certain genomic sequence (Exiqon®, Vedbaek, 
Denmark) (Table 4) and 5 µL of SYBR® Green Master mix, according with manufactures’ 
instructions. Primers were received lyophilized and re-suspended with nuclease free water 
(MP Biomedicals, LLC, OH, USA). Amplification reactions were carried out in triplicates on 
a 7500 Sequence Detection System (Applied Biosystems, USA), at 95°C for 10 minutes, 
followed by 45 amplification cycles at 95°C for 10 seconds and 60°C for 1 minute with 
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ramp-rate 1.6˚C/s6 optical read. Each plate also contained two negative template controls 
and serial dilutions of a positive control, consisted of total human prostate RNA (Ambion, 
Austin, Texas, USA) previously converted to cDNA (dilution factor of 10x), which were 
used to construct a calibration curve for each plate to quantify the amount of transcript in 
each reaction.  
A run was considered valid when the further requisites were achieved: a) Slopes of 
each calibration curve above -3.20 corresponding to a PCR efficiency near 100%; b) R2 of 
at least three relevant data points ≥ 0.99; c) No template controls not amplified; d) 
Threshold cycle value for each gene ≤ 40; 
For each sample, the triplicate with a standard deviation greater than 0.38, was 
removed. Also, for quality control, all amplification curves were visualized and scored 
without information of the clinical data. Finally, the ratio obtained by the former 
mathematic operation, which constitutes an index of the percentage of input copies of 
DNA that exist in that sample, was multiplied by 1000 for easier tabulation (expression 
levels = target gene/ average of the two reference genes x1000). The two reference 
genes used for normalization were miR-191 and miR-423-5p as these obtained the lowest 
coefficient of variation in Global microRNA Expression profile, between samples. 
.  
Table 4 - Oligonucleotide target sequences to be studied and amplified by qRT-PCR in this work. 
Target miRNA Mature Sequence to be amplified 
miR-191 CAACGGAAUCCCAAAAGCAGCUG 
miR-130a CAGUGCAAUGUUAAAAGGGCAU 
miR-205 UCCUUCAUUCCACCGGAGUCUG 
miR-145 GUCCAGUUUUCCCAGGAAUCCCU 
miR-423-5p UGAGGGGCAGAGAGCGAGACUUU 
 
 
DNA Methylation Analysis 
 
In Silico Screening for CpG Islands  
In order to confirm that the genes codifying for the miRNAs previously identified 
were putatively regulated by methylation, the presence of CpG islands at their promoter 
region was assessed in silico by Methyl Primer Express v 1.0 CpG as described by Costa 
et al. (Costa et al., 2010). The criteria used to define a CpG island were the existence of a 
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minimum stretch of 100 bp with at least 50% CG content and a ratio observed/expected 
CpG of at least 0.6. The minimal distance to differentiate two different adjacent CpG 
islands was 100 bp. For that, sequences of the candidate miRNA genes were obtained 
from the human genome database (http://www.ensembl.org). CpG islands were searched 
in a region up to 5000 bp 5’-upstream from the mature miRNA. The miRNAs that did not 
contain any CpG island were excluded from further analyses. The methylation status of 
the miRNAs’ genes harboring a CpG was further assessed. 
 
 
DNA Extraction 
DNA from all clinical samples was extracted by the phenol-chloroform, according 
to standard protocol, as described by Pearson et al. (Pearson and Stirling, 2003). Thus, 
tissue digestion was achieved by adding 2700 µL of SE solution (75mM NaCl; 25 mM 
EDTA) 300 µL of 10% SDS (Sodium Dodecyl Sulfate) and 25 µL of proteinase K (20 
mg/mL) (Sigma-Aldrich®, Germany) to each tube, followed by incubation overnight in a 
water-bath at 55ºC until total digestion was achieved. When necessary, the incubation 
went for 2 or 3 days, and proteinase K was added twice a day, during the incubation 
period. After digestion, extraction was completed with phenol/chloroform [Sigma, 
Germany]/ [Merck, Germany] in Phase Lock GelTM tubes. After centrifugation (20 minutes 
at 4000 rpm), the upper aqueous phase was transferred to a new tube. The DNA 
precipitation followed through with 1000 µL of 100% cold ethanol and 165 µL of 
ammonium acetate 7.5 M ammonium acetate (Sigma-Aldrich®, Germany), mixed and 
incubated overnight at -20ºC in order to promote DNA precipitation. The samples were 
washed in 70% ethanol solution and the pellets were air dried and eluted in 30 µL of 
sterile distilled water (B. Braun, Melsungen, Germany). DNA concentrations were 
determined using a NanoDrop ND-1000 spectrophotometer (Nanodrop Technologies, 
USA) and stored at - 20ºC until used.  
 
 
Sodium Bisulfite Treatment of DNA 
The basic principle of sodium bisulfite modification of DNA is that all unmethylated 
cytosines are deaminated, sulphonated and then converted to thymines, whereas 
methylated cytosines remain unaltered in the presence of NaOH and sodium bisulfite 
(Esteller, 2009, Tost, 2009). Consequently, the sequence of treated DNA will differ 
depending on whether the DNA is originally methylated or not (Fig.16). 
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Figure 16 – Diagram of bisulfate modification of Methylated and Unmethylated DNA. Adapted from 
(Esteller, 2009)  
 
In detail, the genomic DNA fragments are denatured to single stranded DNA, for a 
more effective bisulfite action, secondly cytosines form adducts, across the 5-6 double 
bond with an oxidant reagent such as bisulfate ion, which promotes deamination of the 
cytosine to give a uracil-bisulfite derivate. Thus, a subsequent alkali treatment will form a 
uracil by the removal of the sulphonate group (Fig. 17) (Tost, 2009, Clark et al., 1994). 
This reaction is highly specific and is controlled by pH, bisulfate concentration, 
temperature and the length of the genetic material (Clark et al., 1994). After this reaction 
the  strands of DNA are no longer complementary, allowing its analyses by PCR methods 
(Tost, 2009). 
 
 
 
 
 
 
 
 
 
 
Figure 17 – Schematic diagram of bisulfite conversion reaction. Adapted from (Clark et al., 1994) 
Genomic DNAs from tissues and urine were modified by sodium bisulfite, using EZ 
DNA Methylation-Gold kit (Zymo Research, Orange, CA, USA) and this procedure was 
performed in accordance to manufacturer’s guidelines. Briefly, in a PCR tube,1 µg of DNA 
in a total volume of 20 µL in sterile distilled water (B. Braun, Melsungen, Germany) was 
added to 130 µL of the CT conversion Reagent of the above mentioned commercial kit 
and incubated in a Veriti® Thermal Cycler (Applied Biosystems, Foster City, CA,USA) for 
10 minutes at 98ºC, and 180 minutes at 64ºC, in order to complete the cited chemical 
reaction. Following, the DNA was recovered in 600 µL using M-Binding buffer placed in a 
Zymo-Spin IC™ column and centrifuged for 30 seconds at 10,000 rpm, followed by a 
- 33 - 
 
cleanup step with M-Wash Buffer in the column. After eliminating the M-Wash Buffer from 
the column, 200 μL of M-Desulphonation Buffer were added and the DNA was submitted 
to desulphonation by this buffer for 20 minutes at room temperature. After a centrifugation 
to remove M-Desulphonation Buffer from the Column, DNA was washed twice with M-
Wash Buffer. Finally, the column was placed in a new 1.5 mL-tube and DNA was eluted 
by incubation with 30 μL of sterile bidistilled water (B.Braun, Melsungen, Germany) for 5 
minutes at room temperature followed by a centrifugation at 12,000 rpm for 30 seconds. 
This last step was performed again to obtain a total volume of 60 μL. CpGenome™ 
Universal Methylated DNA (Millipore, CA, USA) and CpGenome™ Universal 
Unmethylated DNA (Millipore, CA, USA) were also modified. CpGenome™ Universal 
Methylated and Unmethylated DNA (Millipore, CA, USA) were eluted in a final volume of 
30 μL. Finally, bisulfite modified DNA was stored at -50ºC until further use. 
 
 
Methylation Specific Polymerase Chain Reaction (MSP) 
MSP constitutes both a sensitive and specific methodology for evaluating promoter 
hypermethylation of CpG islands (Herman et al., 1996, Tost, 2009). Hence, after bisulfite 
modification, the amplification is possible using specific primers that can distinguish 
methylated from unmethylated DNA. To insure specificity they must include at least two 
CG residues, with at least one of them located near the 3’ region and also include non-
CpG cytosines to amplify only modified DNA (Tost, 2009). The primers sequences, 
chosen from regions containing frequent cytosines, were designed using Methyl Primer 
Express v 1.0, for miR-130a, while miR-205 (Bhatnagar et al., 2010) and miR-145 (Suh et 
al., 2011) have been already published elsewhere (Table 5). In the present study, MSP 
was used to assess primers’ specificity for the methylated sequence, to further be 
analyzed by real-time quantitative methylation-specific PCR (qMSP). For that, 
CpGenome™ Universal Mehylated DNA (Millipore, CA, USA), previously modified, was 
used as a positive control for methylation, while negative controls were modified from 
CpGenome™ Universal Unmehylated DNA (Millipore, CA, USA). Water blanks were also 
included in each assay. Thus, bisulfite modified DNA (2 uL) was amplified by PCR, using 
a primer pair for methylated and unmethylated CpG sequences, in a total volume of 20 uL, 
each. The amplification mix contained 0.4 µL of 10 mM of dNTPs mix (Fermentas, 
Ontario, Canada), 1 µL of each pair (forward and reverse) of methylated or nonmethylated 
primers at 10 µM, 2 µL of 10x DyNAzyme™ II Hot Start Reaction Buffer (Finnzymes, 
Finland), 0.24 µL of DyNAzyme II Hot Start (2 U/µL) (Finnzymes, Finland) and 14.36 µL of 
sterile distilled water (B. Braun, Melsungen, Germany), according with manufactures’ 
instructions. In each assay negative and positive controls were tested simultaneously for 
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each pair of methylated primers, as well as, a water-blank to assess possible 
contaminations. The amplification conditions were performed as indicated by 
DyNAzyme™ II Hot Start manufacturer’s conditions, at 94°C for 10 minutes, followed by 
35 cycles at 94°C for 30 seconds, for each pair of primers an optimal annealing 
temperature (60ºC for miR-130a, 64ºC for miR-145, and 59ºC for miR-205) was 
performed for 30 seconds and 72°C for 30 seconds, followed by a final extension for 5 
minutes at 72°C. The amplification products were loaded on a 2% agarose gel, stained 
with ethidium bromide, and visualized under UV illumination.  
 
Table 5 – Oligonucleotide primers used for MSP and promoter methylation levels quantification by qMSP. 
 
 
Real-time Quantitative MSP (qMSP) 
QMSP was performed for the same miRNAs in order to quantify the levels of CpGs 
promoter methylation, of each identified miRNAs. To date, most of the studies detecting 
miRNAs hypermethylation have used conventional MSP, a sensitive but not quantitative 
assay. Thus, using the same primers previously used for MSP fluorescence based, qMSP 
were performed using Power SYBR® Green PCR Master Mix (Applied Biosystems, USA), 
as performed by Savva-Bordalo et al. (Savva-Bordalo et al., 2010). Briefly, 2 µL of 
modified DNA from tissue and urine samples were amplified in a final reaction volume of 
20 µL, which consisted of: 10 µL of Master Mix, 1 µL of forward and reverse methylated 
primers at 10µM and 7 µL of sterile deionized nuclease free water (MP Biomedicals, LLC, 
OH, USA). Analyses was performed in a 96 well plate in a 7500 Sequence Detection 
System (Applied Biosystems, USA), using the following amplification conditions: 50°C for 
2 minutes, followed by 95°C for 10 minutes, then 45 cycles at 95°C for 15 seconds and 
specific primer annealing temperature [miR-130a, miR-145 and ACTB (used as reference 
gene) at 60ºC, and miR-205 at 59ºC) for 1 minute (Savva-Bordalo et al., 2010). After all 
cycles were completed, a dissociation-curve analysis was performed by the following 
Target miRNA MSP primers 
miR-130a 
Forward Methylated - ATAAATTTTGTCGGGGAGAGC 
Reverse Methylated - AATACCCCGATCAACGAAAA 
miR-145 
Forward Methylated - GGGTTTTCGGTATTTTTTAGGGTAATTGAAGTTTC 
Reverse Methylated - TAAAATACCACACGTCGCCG 
miR-205 
Forward Methylated - GAGTTTAAGTTGCGTATGGAAGC 
Reverse Methylated - AAAACAAATATTTCTTTTATAATCCGAA 
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conditions: 95°C for 15 seconds, 60°C for 20 seconds and 95°C for 15 seconds. Samples 
were run in triplicate and multiple water blanks were used as control for contamination 
(negative control). To build the standard curve, five dilutions (dilution factor of 5x) of the 
same stock of bisulfite modified CpGenome™ Universal Methylated DNA (Millipore, CA, 
USA) were run in each plate. A run was considered valid when the further requisites were 
achieved: a) Slopes of each calibration curve above -3.60 corresponding to a PCR 
efficiency near 100%; b) R2 of at least three relevant data points ≥ 0.99; c) no template 
controls not amplified; d) The positive methylation control had to supply a significant 
methylation signal; e) Threshold cycle value for each gene ≤ 40; f) No negative template 
controls were amplified. 
For each sample, the triplicate with a standard deviation greater than 0.38, was 
removed. Also for quality control, all amplification curves were visualized and scored 
without knowledge of the clinical data. Finally, the ratio generated by the former 
mathematic operation, which constitutes an index of the percentage of input copies of 
DNA that are completely methylated at the specific primer site was multiplied by 1000 for 
easier tabulation (methylation levels = target gene/reference gene × 1000) (Savva-
Bordalo et al., 2010). To classify samples as methylated or unmethylated, an empirical 
cutoff value was selected based on the highest methylation ratio value obtained for NPT 
or HD samples, ensuring an absolute specificity of the assay.  
 
 
Identification of Prostate Cancer Cellular Pathways Targeted 
by Epigenetically Deregulated MiRNAs 
After the identification and validation of 3 epigenetically regulated miRNAs, we 
investigated their putative target genes and forecast its implication to prostatic 
carcinogenesis.  
 
Bioinformatics’ Uncovering of MiRNAs Targets 
The prediction of miRNA-mRNA interactions remains a challenging task due to the 
interactions complexity and still a limited knowledge of the entire process. There are 
numerous target prediction algorithms to find and speculate numerous targets that exploit 
different approaches and methods to predict such interactions. The current available 
algorithms can be divided in two categories based on the use or non-use of conservation 
comparison. The algorithms based mostly on conservation criteria are for example 
miRanda, PicTar, TargetScan and DIANA-microT while PITA and rna22 belong group of 
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those who use other parameters such as free energy of binding or secondary structures of 
3’UTRs that can promote or prevent miRNA binding (Witkos et al., 2011). There is no 
consensus regarding the best algorithm, since all have advantages and disadvantages. 
Therefore, the algorithm that we have used was DIANA-microT, which has been already 
widely used in several studies (Albertini et al., 2011, Maragkakis et al., 2009, Formosa et 
al., 2012).  
This algorithm uses a 38 nt-long frame that is moved along the 3’UTR, and the 
minimum energy of potential miRNA binding is measured and compared with the energy 
of 100 per cent complementary sequence bound to the 3’UTR region (Witkos et al., 2011). 
Additionally, this database searches for sites with canonical central bulge, requiring 7-9 nt-
long complementary in 5’ region of target miRNA (Witkos et al., 2011).  
This database considers mainly conservative alignment for scoring but also non-
conservative sites and it provides a probability of existence for each result depending on 
its pairing and conservation profile (Witkos et al., 2011). Therefore, for the identification of 
the pathways that are targeted by the identified miRNA, a higher and specific threshold 
score of 0.9 was used according to previously reported (Vlachos et al., 2012). 
All the targets predicted by this algorithm will be properly validated in future 
studies.  
 
Statistical Analysis 
The Wilcoxon Signed Rank non-parametric test was performed for two-groups 
comparison of gene expression (Khan, 2004) and all miRNAs which showed a significant 
differential expression (p<0.05) were further considered for analysis. 
The frequency of methylated cases, as well as the median and interquartile range 
of miR-130a, miR-145 and miR-205 promoter methylation was determined in PCa tissues 
and NPT. Also, the frequency of methylated cases as well as the median and interquartile 
range of miR-130a and miR-205 promoter methylation levels were determined in PCa 
patients and HD urine samples. To classify each sample as methylated or unmethylated 
an empirical cutoff value was established based on the higher methylation level observed 
in NPT tissues or HD urines, respectively. Differences in quantitative levels between NPT, 
HGPIN and PCa tissues or PCa and HD urines were assessed by the nonparametric 
Kruskal-Wallis test, followed by Bonferroni-adjusted Mann-Whitney U test for pairwise 
comparisons, when appropriate. 
For statistical analysis purposes, PCa samples were divided into three Gleason’s 
Score (GS) categories (GS < 7, GS = 7, and GS > 7). Clinical stage at diagnosis 
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comprised two categories (stage II and III). The relationship between methylation or 
expression levels and other clinicopathological variables such as serum PSA levels at the 
time of diagnosis, GS and pathological stage were evaluated using the Kruskal-Wallis or 
the Mann-Whitney U tests, as appropriate. The Spearman non parametric correlation test 
was used to correlate methylation levels with age and also to correlate methylation levels 
with expression levels of each miRNA in the 101 PCa cases selected for both analyses. 
For the purpose of examining the biomarker potential, sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV) and accuracy of miR-
130a, miR-145 and miR-205, in tissue samples, and of miR-130a and miR-205, in urine 
samples, alone or in association, were calculated. In addition, multivariate logistic 
regression was used to examine associations between miRNAs with biomarker potential. 
For multivariate logistic regression the backward stepwise (Wald) selection method was 
used. Then, a receiver operator characteristics (ROC) curve was performed by plotting the 
true-positive rate (sensitivity) against the false-positive rate (1-specificity) and the area 
under the curve (AUC) was also calculated individually and for combination of the 
selected miRNAs.  
Two sided p-values were considered significant when inferior to 0.05 for all tests, 
with Bonferroni’s correction, when appropriate. Statistical analyses were performed using 
SPSS version 20.0. 
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RESULTS 
 
Clinical and Pathological Characteristics 
Tissue samples from 105 PCa, 56 HGPIN lesions, and 14 NPT samples were 
tested. The clinical and pathological characteristics of the patients are illustrated in Table 
6. No significant differences were found for the median age of NPT, HGPIN and PCa 
patients, using the Kruskal-wallis test. The clinical characteristics of the patient who 
provided urine samples are illustrated in Table 7. However significant differences were 
found in urine samples, for the median age of HD and PCa patients (p<0.001), using the 
Mann–Whitney U test. 
Table 6 – Clinical and pathological characteristics of patients from which tissue samples were obtained. 
Clinicopatholgical Features PCa HGPIN NPT 
Patients, n 101 56 14 
Median age, years* 64 (49 - 74) 65 (53 - 75) 65 (45 - 80) 
PSA (ng/mL), median 
(range)* 
7.6 (3.4 - 35.5) n.a. n.a. 
Pathological Stage, n (%) 
pT2 56 (55.4) n.a. n.a. 
pT3 45 (44.6) n.a. n.a. 
Gleason Score, n (%) 
< 7 30 (29.7) n.a. n.a. 
= 7 56 (55.4) n.a. n.a. 
> 7 15 (14.9) n.a. n.a. 
Abbreviations: NPT- Morphologically Normal Prostate Tissue; HGPIN- High Grade Prostatic Intraepithelial 
Neoplasia; PCa- Prostate Cancer and n.a.- Not Applicable 
Table 7 – Gender and age distribution of patients which provided urine samples for this study. 
 
      
 
 
 
 
 
 
Abbreviations: PCa- Prostate Cancer; HD- Healthy Donors 
 HD PCa 
Patients, n 15 39 
Gender, n (%) 
Male 15 (100%) 39 (100%) 
Female 0 (0%) 0 (0%) 
Median age, yrs 
(range) 
52 
(43-64) 
65 
(52-88) 
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Identification of Epigenetically Regulated MiRNAs  
 After comparing the expression values between PCa tissues and NPT, only 173 
miRNAs, out of the 740 analyzed, shown to be differently expressed with a p<0.05 by the 
Signed Rank non-parametric test. After applying the previously mentioned fold variation 
cut-off, 47 miRNAs were significantly downregulated, whereas 5 miRNAs were found to 
be upregulated (Fig. 18). From the downregulated miRNAs, the highest fold variation 
values were displayed by miR-187 (~3.0 fold) and miR-224, miR-31*, miR-548b-3p, miR-
193b*, miR-205 and miR-221*(~2.0 fold) (Table 8). Conversely, miR-449a and miR-32 
were upregulated with a fold variation of 4.0 and 3.0, respectively. 
 
 
 
 
Figure 18 – Number of differentially expressed miRNAs in PCa tissues concerning respective fold variations. 
  
Expression<-1.0 
Expression -1.0; 0 
Expression 0; 1.0 
Expression >1.0 
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Table 8 – Downregulated miRNAs with a fold variation lower than -1.0. 
* Wilcoxon Signed Rank non-parametric test 
  
Ranking miRNA Mean Fold Variation (Log 2) Chromosome localization P value* 
1 miR-187 -3.07 18q122 P=0.002 
2 miR-224 -2.72 Xq28 P=0.013 
3 miR-31* -2.47 9p213 P=0.027 
4 miR-548b-3p -2.43 6q2231 P=0.013 
5 miR-193b* -2.18 16p1312 P=0.002 
6 miR-205 -2.13 1q322 P=0.004 
7 miR-221* -2.02 Xp113 P=0.014 
8 miR-27b* -1.91 9q2232 P=0.019 
9 miR-204 -1.84 9q2112 P=0.002 
10 miR-624* -1.81 14q12 P=0.002 
11 miR-628-3p -1.79 15q213 P=0.036 
12 miR-502-3p -1.78 Xp1123 P=0.024 
13 miR-214 -1.73 1q243 P=0.036 
14 miR-221 -1.72 Xp113 P=0.008 
15 miR-555 -1.71 1q22 P=0.024 
16 miR-139-5p -1.67 11q134 P=0.014 
17 miR-100 -1.67 11q241 P=0.024 
18 miR-505* -1.64 Xq271 P=0.006 
19 miR-338-5p -1.60 17q253 P=0.013 
20 miR-125b-2* -1.54 21q211 P=0.008 
21 miR-145* -1.54 5q32 P=0.024 
22 miR-328 -1.51 16q221 P=0.019 
23 miR-1271 -1.49 5q35 P=0.002 
24 miR-224* -1.49 Xq28 P=0.024 
25 miR-145 -1.48 5q32 P=0.006 
26 miR-455-3p -1.42 9q32 P=0.004 
27 miR-30a* -1.42 6q13 P=0.024 
28 miR-222 -1.40 Xp113 P=0.004 
29 miR-193b -1.37 16p1312 P=0.028 
30 miR-133b -1.35 6p122 P=0.036 
31 miR-300 -1.29 14q3231 P=0.036 
32 miR-143* -1.29 5q32 P=0.024 
33 miR-1468 -1.29 Xq112 P=0.024 
34 miR-296-5p -1.28 20q1332 P=0.036 
35 miR-509-3p -1.27 Xq273 P=0.014 
36 miR-29b-1* -1.19 7q323 P=0.024 
37 miR-320a -1.17 8p213 P=0.014 
38 miR-23b* -1.16 9q2232 P=0.004 
39 miR-181a-2* -1.12 9q333 P=0.028 
40 miR-675b -1.12 11p155 P=0.028 
41 miR-193a-5p -1.10 17q112 P=0.014 
42 miR-23b -1.09 9q2232 P=0.014 
43 miR-138 -1.03 16q13 P=0.046 
44 miR-130a -1.03 11q121 P=0.001 
45 miR-378 -1.03 5q32 P=0.036 
46 miR-1181 -1.03 19p132 P=0.036 
47 miR-99b -0.99 19q1341 P=0.014 
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Additionally, the relative expression fold variation of the same 740 miRNAs was 
assessed for the three PCa cell lines (LNCaP, VCaP and PC3) (treated with 1 µM 5-AZA-
DC vs untreated). The results for each cell line are depicted in Figure 19. In PC3 cell line, 
227 miRNAs were re-expressed after treatment, whereas there were 202 miRNAs for 
LNCaP and 218 miRNAs for VCaP. Interestingly, only 18 miRNAs were commonly re-
expressed in the three treated cell lines, while 120 miRNAs were re-expressed in two out 
of the three treated cell lines. Of these, only miR-130a, miR-145, miR-205, miR-509-3p, 
miR-23b*, miR-455-3p and miR-1181 were significantly downregulated in PCa, and thus, 
identified as putatively regulated by gene promoter methylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 – The Venn diagram shows the number of miRNAs re-expressed with a fold variation higher than 
1.0 in LNCaP, PC-3 and VCaP after treatment with 5-AZA-DC, in comparison with the non treated. 
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Finally, the expression status of these miRNAs was verified in normal prostate 
through their search in www.microrna.org database. Hence, miR-509-3p and miR-1181 
miR-23b* were excluded of further analysis, since no information was found, concerning 
its expression in normal prostatic tissue. Concerning miR-455-3p it had no CpG island 
locate 5000 bp upstream. 
Importantly, concerning the 3 identified miRNAs, we describe a novel miRNA, miR-
130a, which has never been reported to be epigenetically regulated, and miR-145, miR-
205 both already described to be regulated by methylation in PCa cell lines and tissues.  
A flow-chart of the strategy used for the identification of putatively epigenetic 
regulated miRNAs is depicted in Figure 20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 – Overview of the screening approach performed in this study. A combination of in silico analyses, 
molecular studies in human PCa cell lines, and analysis of primary PCa and health prostate tissue specimens used for 
the identification of miRNAs genes affected by differential methylation in human PCa. 
Check the microRNA.org database 
 18 miRNAs re-expressed in 3/3 5-Aza-DC treated cell lines 
vs. mock 
 120 miRNAs re-expressed in 2/3 5-Aza-DC treated cell lines 
vs. mock 
(fold variation > 1.0) 
4 miRNAs Expressed in Normal Prostate 
3 miRNAs with a CpG island at 5 Kb from mature 
sequence: 
miR-130a, miR-145 and miR-205 
 
In Sillico screening for CpG Island of the 
candidate miRNA’s gene promoters 
 
qRT-PCR miRNA plates  
assessing  
740 miRNAs candidate genes  
47 miRNAs Downregulated 
in PCa vs. NPT 
 
(fold variation < -1.0) 
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Analysis of MiRNAs Promoter Methylation in Tissues 
After testing the primers for each miRNA by conventional MSP, and verifying their 
specificity (data not shown), qMSP analysis was performed to determine the methylation 
levels of the promoter regions of miR-130a, miR-145 and miR-205 in tissue samples. 
An empirical cutoff value (highest methylation level observed in NPT) was used to 
categorize cases as methylated vs. unmethylated. Thus, miR-130a showed the highest 
frequency of methylation in PCa (82.2%), followed by miR-205 (35.6%) and miR-145 
(26.73%). Median and interquartiles values for the methylation levels are represented on 
Table 9. Differences among the three groups of tissues for the methylation frequencies 
and methylation levels were statistically significant for the 3 tested miRNAs (Kruskall-
Wallis test, p<0.0001 for both).  
 
Table 9 – Frequency and distribution of the methylation levels for each miRNA in PCa tissue samples  
 PCa HGPIN NPT  
Gene n (%) Median (IQR) n (%) Median (IQR) n (%) Median (IQR) P Value* 
miR-130a 83 (82.17%) 
200.91  
(144.86- 283.26) 
23 (41.07%) 
87.06 
 (29.36- 192.93) 
0 (0%) 
27.78 
 (13.18- 56.03) 
<0.0001 
miR-145 27 (26.73%) 
346.11 
 (216.04- 471.39) 
23 (41.07%) 
442.83  
(313.80- 558.57) 
0 (0%) 
117.98  
(75.28- 253.26) 
<0.0001 
miR-205 36 (35.64%) 
345.30  
(204.52- 640.41) 
24 (42.86%) 
266.40  
(183.81- 376.68) 
0 (0%) 
58.09  
(17.62- 177.22) 
<0.0001 
Abbreviations: IQR- Interquartile Range; NPT- Morphologically Normal Prostate Tissue; HGPIN- High Grade 
Prostatic Intraepithelial Neoplasia; PCa- Prostate Cancer; * Kruskall-Wallis test 
 
Indeed, pair-wise comparisons showed that in PCa the methylation levels of the 3 
miRNAs were significantly higher than those of NPT (Bonferroni-adjusted Mann-Whitney 
U test, p<0.0001) (Fig. 21, 22 and 23). The same trend was verified concerning the 
comparison between PCa and HGPINs, in which for miR-130a (Fig. 21) (Bonferroni-
adjusted Mann-Whitney U test, p<0.0001) and for miR-205 (Fig. 23) (Bonferroni-adjusted 
Mann-Whitney U test, p=0.004) the highest levels were found in the tumor samples. 
Contrarily, for miR-145 significantly higher methylation levels were observed in HGPIN 
(Fig. 22) (Bonferroni-adjusted Mann-Whitney U test, p=0.011). Moreover, the methylation 
levels displayed by HGPIN lesions were also significantly higher than by NPT [miR-130a 
(Bonferroni-adjusted Mann-Whitney U test, p=0.003), miR-205 (Bonferroni-adjusted 
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Mann-Whitney U test, p<0.0001) and miR-145 (Bonferroni-adjusted Mann-Whitney U test, 
p<0.0001)] (Fig. 21, 22 and 23). 
 
           
Figure 21 – Distribution of miR-130a promoter methylation levels in prostatic tissue samples. Abbreviations: 
NPT- Morphologically Normal Prostate Tissue; HGPIN- High Grade Prostatic Intraepithelial Neoplasia; PCa- Prostate 
Cancer 
 
 
           
Figure 22 – Distribution of miR-145 promoter methylation levels in prostatic tissue samples. Abbreviations: 
NPT- Morphologically Normal Prostate Tissue; HGPIN- High Grade Prostatic Intraepithelial Neoplasia; PCa- Prostate 
Cancer 
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Figure 23 – Distribution of miR-205 methylation levels in prostatic tissue samples. Abbreviations: NPT- 
Morphologically Normal Prostate Tissue; HGPIN- High Grade Prostatic Intraepithelial Neoplasia; PCa- Prostate Cancer 
 
 
No significant correlations were found between methylation levels of the target 
genes and any of the clinical-pathological variables (age, pre-operative serum PSA, 
Gleason score or pathological stage). 
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mRNA Relative Expression Levels in Tissue 
The expression levels of the three miRNAs, miR-130a, miR-145 and miR-205, 
were also determined in the same series of tissue samples. Indeed, miR-130a (Mann-
Whitney U test, P=0.004) and miR-205 (Mann-Whitney U test, P<0.0001) were 
significantly downregulated in PCa, as shown in Figures 24 and 26. 
 
         
Figure 24 – Distribution of miR-130a transcript expression levels in prostatic tissues. Abbreviations: NPT- 
Morphologically Normal Prostate Tissue; PCa- Prostate Cancer; Av- Average 
 
 
           
Figure 25 – Distribution of miR-145 transcript expression levels in prostatic tissue. Abbreviations: NPT- 
Morphologically Normal Prostate Tissue; PCa- Prostate Cancer; Av- Average 
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Figure 26 – Distribution of miR-205 transcript expression levels in prostatic tissue. Abbreviations: NPT- 
Morphologically Normal Prostate Tissue; PCa- Prostate Cancer; Av- Average 
 
 
 
Concerning miR-145, although the same trend has been observed, no statistical 
significance was attained (Fig. 25). 
No correlation was found between transcript expression levels of any of the 
analyzed miRs and respective gene promoter methylation levels. Moreover, no significant 
correlations were found between the transcript levels of miR-130a and miR-145 and 
clinical-pathological variables (age, pre-operative serum PSA, Gleason’s score or 
pathological stage). However, concerning miR-205, significant correlation was found 
between transcript levels and both Gleason score and pathological stage. Interestingly, 
miR-205 expression levels were lower in high Gleason’s scores tumors (Kruskall-Wallis 
test, p=0.001). Indeed, significant differences were found between GS<7 and GS=7 
(p=0.018), between GS=7 and GS>7 (p=0.026) and between GS>7 and GS<7 (p=0.001) 
by the Mann-Whitney U test (Fig. 27). Furthermore, miR-205 lower expression levels 
inversely correlated with pathological stage by the Mann-Whitney U test (p=0.006) (Fig. 
28). 
 
 
 
  
- 49 - 
 
           
Figure 27 – Expression levels of miR-205 in samples of 101 PCa prostatectomies according to Gleason’s     
Score. Abbreviations: GS- Gleason’s score; Av- Average 
 
 
 
 
 
           
Figure 28 – Expression levels of miR-205 in samples of 101 PCa prostatectomies according to clinical stage. 
Abbreviations: CS- clinical stage; Av- Average  
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Evaluation of the Biomarkers Diagnostic Potential Using 
Tissue and Urine Samples 
 
Performance of MiR-130a, MiR-205 and MiR-145 Methylation as Tumor 
Markers in Tissue 
The diagnostic performance of the three miRNAs was assessed using the cutoff 
values of methylation levels previously referred and determined for each of these gene 
promoters (117.54 for miR-130a, 463.15 for miR-145 and 298.39 for miR-205). Validity 
and information estimates for each miRNA or the best combination of genes are displayed 
in Table 10. 
 
Table 10 – Diagnostic performance of selected miRNAs methylation as a PCa biomarker, alone or in 
association. 
 
 
Parameter - Value (%) 
Gene Sensitivity Specificity PPV NPV Accuracy 
miR-130a 82.18 100 100 43.75 84.35 
miR-145 26.73 100 100 15.91 35.65 
miR-205 64.36 100 100 28.00 68.70 
miR-130a  and miR-205 89.11 100 100 56.00 90.43 
miR-130a, miR-145 and 
miR-205 
91.09 100 100 60.87 92.17 
 Abbreviations: PPV - Positive Predictive Value; NPV Negative Predictive Value (NPV) 
 
 
Although, a specificity of 100% was apparent for all tested miRNAs, the sensitivity 
has ranged from 27% to 82%, for each miRNA alone. The best sensitivity was achieved 
combining in the same panel the methylation analysis of two miRNAs (miR-130a and miR-
205). According to the model of logistic regression applied, the inclusion of miR-145 in the 
panel, did no increment significantly the performance of the two miRNAs-panel. ROC 
curve analysis allowed for the determination of the AUC (95% CI) for each miRNAs gene: 
0.956 (0.917- 0.996) for miR-130a, 0.828 (0.710- 0.946) for miR-145 and 0.907 (0.832-
0.982) for miR-205 (Fig. 29). The ROC curve based on the above mentioned panel of two 
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markers (miR-130a and miR-205) resulted in an area under the curve (AUC) of 0.970 
(0.941-0.998), at a significance of P<0.0001, by the multivariate logistic regression Wald 
test (Fig. 30).  
 
 
Figure 29 – Receiver operating characteristic curve in PCa tissue for each individual gene (miR-130a, miR-
205 and miR-145). 
 
            
Figure 30 - Receiver operating characteristic curve in PCa tissue for the best combination of two genes (miR-
130a and miR-205). 
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Performance of MiR-130a and MiR-205 Methylation as Tumor Markers in 
Urine Samples 
We have additionally investigated the methylation status of the promoter region of 
the miRNAs panel which have shown the best performance in terms of sensitivity, 
specificity and ROC curve (thus miR-145 was not tested), in distinguishing PCa patients 
from controls in tissue samples, in urine samples. Nevertheless, due to time constrains, 
we have only performed a preliminary study in a few number of urine sediments: 39 PCa 
urine patients and 15 urine samples obtained from HD. 
Interestingly, the Bonferroni-adjusted Mann-Whitney U test revealed that miR-130a 
methylation levels were significantly higher in urine samples from PCa than from healthy 
donors (p=0.015) (Fig. 31), however the same was not demonstrated for miR-205.  
The possible diagnostic performance of the miR-130a alone was assessed using 
the cutoff values of methylation levels of 114.05. Validity and information estimates are 
displayed in Table 11. 
 
                
Figure 31 – Distribution of the methylation levels of miR-130a in urine samples. Abbreviations: HD- Healthy 
Donnors; PCa- Prostate Cancer 
 
 
 
Table 11 – Diagnostic performance of miR-130a methylation in urine samples. 
 
Parameter Value (%) 
Sensitivity 25.64 
Specificity 100 
PPV 100 
NPV 34.09 
Accuracy 46.30 
Abbreviations: PPV - Positive Predictive Value; NPV Negative Predictive Value (NPV) 
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MiRNAs Potential Targets 
In order to investigate possible target genes and respective signaling pathways of 
the three methylation regulated miRNAs previously identified, a well know database 
DIANA-microT was surveyed, using the described criteria in the material and methods 
section. Possible target pathways of miR-130a, miR-145 and miR-205 are listed in Table 
12, Table 13 and Table 14, respectively. Globally, several critical pathways involved in 
tumor progression seem to be targeted by the three miRNAs herein identified as 
epigenetically deregulated in PCa. 
 
 
 
Table 12 – Possible pathways targeted by miR-130a. 
 
 
 
 
 
 
Putative Target Pathways Gene Name -ln(value) 
TGF-beta signaling pathway 
LTBP1, ROCK1, ZFYVE9, SMAD5, ACVR1, SKP1A, 
NOG, INHBB, GDF6, PPP2R1B, ACVR2B, TGFBR2, 
EP300 
13.84 
Calcium signaling pathway 
PDE1C, PLN, PDGFRA, LHCGR, ADCY1, ERBB3, 
ATP2A2, SLC8A1, ITPR1, ADCY2, SPHK2, GRIN2A, 
PLCB1, ERBB4 
7.01 
Wnt signaling pathway 
WNT2B, NFATC2, ROCK1, SKP1A, DAAM1, WNT1, 
FBXW11, PPP2R1B, NLK, PLCB1, EP300, FZD6 
4.46 
Ubiquitin mediated proteolysis 
UBE2D1, UBE2D2, HERC3, BIRC6, CUL3, UBE2W, 
SKP1A, FBXW11, UBE4B, ANAPC5, CUL5 
4.35 
Gap junction 
PDGFRA, GJA1, ADCY1, ITPR1, PRKG1, ADCY2, 
SOS1, PLCB1 
3.15 
Cell cycle 
E2F3, YWHAB, CDKN1A, GADD45A, E2F2, 
CDC14A, SKP1A, ANAPC5, EP300 
3.07 
mTOR signaling pathway TSC1, PRKAA1, ULK2, IGF1 2.94 
Phosphatidylinositol signaling 
system 
SYNJ1, ITPR1, PTEN,PTENP1, ITPK1, PLCB1 
2.28 
MAPK signaling pathway 
NFATC2, PDGFRA, GADD45A, MAP3K4, PPM1B, 
SOS1, DUSP16, RPS6KA5, NLK, HSPA8, TGFBR2, 
RASA1, MAP3K12, MAX 
2.22 
Adherens junction PTPRM, MET, WASL, NLK, TGFBR2, EP300 2.21 
Focal adhesion 
PDGFRA, MET, ROCK1, CAV2, ITGB8, SOS1, 
PTEN,PTENP1, PAK6, ITGA11, COL2A1, IGF1, 
ITGA5 
2.09 
ABC transporters  ABCA1, ABCC5, ABCD3, ABCB7 1.86 
Ether lipid metabolism ENPP6, LYCAT, PAFAH1B1 1.37 
ErbB signaling pathway CDKN1A, ERBB3, SOS1, PAK6, ERBB4, EREG 1.34 
Methionine metabolism DNMT1, MAT2B 0.93 
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Table 13 – Possible pathways targeted by miR-145. 
 
 
 
Table 14 – Possible pathways targeted by miR-205. 
  
Possible Pathways Gene Name -ln(value) 
Adherens junction 
ACTB, IGF1R, PTPRF, YES1, NLK, TGFBR2, ACTG1, 
SMAD4, SMAD3 
21.3 
TGF-beta signaling pathway 
ZFYVE9, SMAD5, SKP1A, INHBB, TGFBR2, SMAD4, 
SMAD3 
8.67 
Wnt signaling pathway 
FZD7, CTNNBIP1, SKP1A, PPP3CA, NLK, CCND2, 
SENP2, SMAD4, SMAD3 
8.04 
Tight junction 
ACTB, MAGI2, IGSF5, VAPA, YES1, MPP5, ACTG1, 
EPB41L3 
6.7 
Focal adhesion 
ACTB, FN1, IGF1R, FLNB, ITGB8, CCND2, ACTG1, 
PAK7 
3.45 
Cell adhesion molecules  MPZL1, CD40, CDH2, PTPRF, ITGB8, HLA-DRB5 3.38 
p53 signaling pathway CDK6, CCND2, BAX, BBC3 3.02 
MAPK signaling pathway 
EVI1, FLNB, MAP4K2, RASA2, PPP3CA, NLK, 
TGFBR2, DUSP6, RASA1 
2.75 
Cell cycle CDK6, SKP1A, CCND2, SMAD4, SMAD3 2.35 
Calcium signaling pathway ADRB3, PTGFR, ERBB3, PPP3CA, NOS1, ERBB4 1.87 
Possible Pathways Gene Name -ln(value) 
Tight junction 
MAGI3, MAGI2, PRKCA, YES1, CLDN11, 
PTEN,PTENP1, PARD6B, EPB41, MYH1 
6.82 
Adherens junction PTPRM, YES1, SORBS1, FGFR1, INSR, SMAD4 6.17 
Ubiquitin mediated 
proteolysis 
UBE2G1, UBE2NL, UBE1, MAP3K1, UBE2N, SIAH1, 
ANAPC5 
3.49 
Notch signaling pathway APH1A, NOTCH2, PCAF 2.35 
ABC transporters – General ABCC9, ABCD1, ABCB7 2.17 
Phosphatidylinositol signaling  PRKCA, INPPL1, PTEN,PTENP1, PLCB1 2.03 
mTOR signaling pathway VEGFA, RPS6KA3, EIF4E 1.79 
Inositol phosphate 
metabolism 
INPPL1, PTEN,PTENP1, PLCB1 
1.79 
Wnt signaling pathway PRKCA, NKD1, SIAH1, PLCB1, NFAT5, SMAD4 1.61 
Cell cycle CDKN2B, CHEK2, CDC25B, ANAPC5, SMAD4 1.57 
TGF-beta signaling pathway INHBA, CDKN2B, SMAD1, SMAD4 1.23 
JAK-STAT signaling pathway TPO 1.23 
Cell adhesion molecules  PTPRM, NRCAM, CLDN11, NRXN1, PTPRC 1.22 
Gap junction PRKCA, NPR2, PLCB1, GNAQ 1.09 
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DISCUSSION 
 
The mechanisms involved in PCa initiation and progression are not fully 
understood at present, demanding the search for yet unidentified molecular alterations 
which underlie tumor heterogeneity. Moreover, the growing concerns about PCa 
overtreatment provide an opportunity for the discovery of novel biomarkers which not only 
are accurately able to detect PCa but are also capable of identifying the aggressive forms 
of the disease. For more than a decade, our research team has been involved in the 
identification of epigenetic-based markers for PCa. The initial research efforts were 
devoted to the characterization of the methylome but the fast evolution of Epigenetics has 
now made clear that other epigenetic alterations, such as histone onco-modifications and 
miRNAs deregulation, might play a critical role in prostate carcinogenesis. Because 
epigenetic mechanisms are closely inter-related, we aimed to identify miRNA genes 
deregulated by promoter methylation in PCa, in an attempt to further illuminate the 
biological mechanisms underlying PCa and, eventually, provide new PCa biomarkers or 
therapeutic targets. Thus, comprehensive in silico analyses were performed to identify 
miRNAs downregulated in PCa and simultaneously re-expressed in response to 5-AZA-
DC exposure in PCa cell lines. Subsequently, the candidate miRNA genes were validated 
in a large number of clinical samples through a qMSP assay and their putative role as 
cancer biomarkers was assessed. In brief, we showed, for the first time, that miR-130a 
downregulation in PCa is due to an epigenetic mechanism, namely aberrant DNA 
promoter methylation, and that this is an early event in prostate carcinogenesis. We have 
also found associations between miR-205 expression and clinical-pathological variables. 
Concerning miR-145, we found that, contrarily to previous reports, it is not significantly 
downregulated in PCa, although it may still be regulated by epigenetic mechanisms. 
Finally, we demonstrated that selected miRNAs promoter methylation may provide useful 
biomarkers for accurate identification of PCa in tissue and urine samples. 
Expression profiling analysis identified several miRNAs differentially expressed in 
PCa samples compared to NPT and most were downregulated (47 vs. 5), a finding which 
is in line with previous reports (Porkka et al., 2007). These results are also in accordance 
with the more comprehensive observation that miRNAs are globally downregulated in 
most human cancers, probably reflecting the lower differentiation of malignant cells (Lu et 
al., 2005). The validity of this first approach is provided by the fact that several miRNAs 
which we found to be downregulated in PCa, including miR-130a, miR-145, miR-221, 
miR-100, miR-99b miR-224 and miR-205, have been already reported by other 
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researchers (Porkka et al., 2007, Szczyrba et al., 2010, Boll et al., 2012, Sun et al., 2011). 
Genomic deletions have been generally considered the cause of miRNA dowregulation 
(Calin et al., 2004), and, indeed, we found that some miRNAs (miR-548b-3p and miR-
30a* at 6q16-22, and miR-328 at 16q) located at frequently deleted regions in PCa (Lu 
and Hano, 2008, Carter et al., 1990) were downregulated in our series. However, 
epigenetic alterations have recently emerged as an alternative mechanism (Bandres et 
al., 2009), and these were the main focus of this study. 
We hypothesized that among epigenetic alterations involved in miRNA 
deregulation, aberrant promoter methylation would be an obvious mechanism, in similarity 
with protein coding genes. Among the relatively large number of candidate miRNA genes 
fulfilling strict selection criteria (re-expressed in at least two cell lines, dowregulated in 
PCa, expressed in normal prostate tissues, and having at the least one CpG island 5000 
bp upstream its mature sequence), only three miRNA genes - miR-130a, miR-145 and 
miR-205 – emerged as candidates for deregulation by promoter methylation. Thus, it is 
likely that the re-expression of a proportion of miRNAs in cell lines may be due to cell 
death induced by 5-AZA-DC, which has cytotoxic properties, as previously suggested 
(Christman, 2002). Indeed, miR-520g and miR-497, which we found to be re-expressed in 
this study, have previously been found to be upregulated in response to treatment with 5-
AZA-DC in bladder cancer cell lines (Yoshitomi et al., 2011). Recent studies have also 
found a few miRNAs regulated by methylation in PCa in cell lines treated with 3 µM of 5-
AZA-DC and later compared to clinical samples (Formosa et al., 2012). The results of this 
study are not fully in line with ours but it must be emphasized that different technologies 
were used for miRNA profiling, as well as higher drug concentrations, a 10 kb upstream 
limit for CpG searching and lower cut-off values considered for downregulation (Formosa 
et al., 2012). These data not only demonstrate that miRNA deregulation in PCa is 
probably a relatively uncommon phenomenon but also that different methodologies are 
likely to yield quite dissimilar results. 
Whereas miR-145 and miR-205 have already been reported as deregulated by 
promoter methylation in PCa, either in cell lines or clinical samples (Hulf et al., 2012, 
Bhatnagar et al., 2010, Hulf et al., 2011), as well as in other tumor models (Wiklund et al., 
2011, Tellez et al., 2011), the main novelty of this study is the identification of miR-130a 
as an epigenetically-regulated miRNA. This finding has been indirectly corroborated by 
the recent demonstration that miR-130a was downregulated in PCa by other researchers, 
although the underlying mechanism was not identified (Boll et al., 2012). Concerning miR-
145, although it was previously found to be downregulated in PCa (Suh et al., 2011), we 
verified that the reduction of expression levels in primary tissues was less dramatic than 
expected. Although methylation is implicated in miR-145 dowregulation, it is likely that 
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other mechanisms are also involved, including monoallelic methylation and histone 
deacetylation. Indeed, PCa cell lines treated with demethylation agent plus a potent 
histone deacetylase inhibitor, display higher re-expression levels of miR-145 than cell 
lines treated with demethylation agent only (Zaman et al., 2010, Ke et al., 2009). The 
same mechanism might explain the lack of correlation between methylation and 
expression levels found not only for miR-145, but also for miR-130a and miR-205. 
Remarkably, miR-205 seems also to be regulated by histone acetylation at lysine 9 of 
histone 3 in PCa cell lines (Hulf et al., 2011). This might explain the inverse correlation 
between miR-205 expression levels with Gleason score and clinical stage and the lack of 
it with promoter methylation levels, in accordance with previous studies which found lower 
miR-205 expression in advanced PCa (Schaefer et al., 2010, Boll et al., 2012). 
This study is the first to demonstrate that promoter methylation of miR-130a, miR-
205 and miR-145 genes precedes the development of invasive PCa as they occur in 
HGPIN lesions, which are generally considered PCa precursors. Interestingly, methylation 
levels in HGPIN are intermediate between those of NPT and PCa, suggesting that this 
epigenetic alteration initially affects only a small subset of morphologically normal 
epithelial cells, which might benefit from a growth / survival advantage. This may foster 
the neoplastic transformation into HGPIN cells and further progression to an invasive 
phenotype, as previously suggested for other genes (Henrique et al., 2006), with which 
these alterations might act in concert. This trend is more obvious for miR-130a and miR-
205, although the higher miR-145 gene promoter methylation levels found in HGPIN vs. 
PCa might be due to epigenetic heterogeneity as suggested for other epigenetic regulated 
genes in prostate carcinogenesis (Henrique et al., 2006). 
A major aim of this study was to assess the biomarker capabilities of epigenetically 
deregulated miRNAs for PCa detection. We found that a panel comprising miR-130a and 
miR-205 promoter methylation is able to accurately discriminate PCa from NPT in tissue 
samples and may, thus, constitute an interesting ancillary tool for histopathological 
assessment of diagnostically challenging prostate lesions. It may also be used in patients 
with clinical suspicion of cancer, abnormal digital rectal examination and persistent 
elevation of PSA, who are to be submitted to a second biopsy. The inclusion of miR-145 in 
the gene panel would only increment sensitivity in 2%, and, thus, we considered that no 
relevant gain was obtained from extending the molecular analysis, especially in minute 
tissue samples. Remarkably, the analysis of miR-130a and miR-205 promoter methylation 
in tissue samples compares well with quantitative promoter methylation analysis of protein 
coding genes for PCa discrimination such as GSTP1 and APC (Henrique et al., 2006). 
However, the performance of miR-130a promoter methylation for PCa detection in urine 
has been disappointing owing to the low sensitivity and NPV (25.64% and 34.09%, 
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respectively), notwithstanding perfect specificity and PPV, providing an overall accuracy of 
46.30%. The performance of this biomarker is undoubtedly inferior to that reported for 
other epigenetic biomarkers developed for PCa detection in urine samples, such as 
GSTP1 (Woodson et al., 2008, Phe et al., 2010). Nevertheless, the feasibility of detecting 
miRNA promoter methylation in prostate clinical samples (urine, in the present study) has 
been clearly demonstrated for the first time and technical refinement must be sought to 
improve the performance of miR-130a promoter methylation. 
The biological impact of the epigenetic deregulation of miR-130a, miR-145 and 
miR-205 was investigated using a bioinformatic tool. Interestingly, all considered miRNAs 
are linked with several cellular pathways such as signal transduction, transcription factors, 
apoptosis and cell adhesion, which are involved in tumor initiation and progression. 
Common pathways targeted by those miRNAs include TGF-beta, MAPK, Wnt, cell cycle 
regulation and adhesion. Remarkably, some of these pathways have been found to be 
upregulated in PCa and potentially enhancing tumorigenicity or invasion, such as TGF-
beta  (Steiner et al., 1994), Wnt signaling (Chen et al., 2004) and some cell cycle 
regulators such as SMADs and CDKs (Aaltomaa et al., 1999, Lu et al., 2007). Thus, it is 
tempting to speculate whether these alterations are due to downregulation of miR-130a, 
miR-145 and miR-205 through promoter methylation, and eventually other epigenetic 
mechanisms. Recent reports emphasize the role of these miRNAs in cancer. Concerning 
miR-130a deregulation, it  has been associated with authophagy and DICER complex 
(Kovaleva et al., 2012), angiogenesis (Chen and Gorski, 2008), as well as to androgen 
receptors co-regulators and MAPK signaling (Boll et al., 2012). Moreover, miR-205 has 
been associated with invasion and cell motility as a part of epithelial-to-mesenchymal 
transition (Gandellini et al., 2009) and apoptosis (Bhatnagar et al., 2010), whereas miR-
145 has been linked with cell growth, migration (Fuse et al., 2011) and angiogenesis (Xu 
et al., 2012). These reports are in line with our findings. For instance, androgen signaling 
activity is considered a key molecular change in the transition from normal prostate 
epithelium to HGPIN as well as in PCa progression (Tomlins et al., 2007). Clearly, 
functional studies are now required to validate these interesting findings. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 Although epigenetic aberration affecting protein coding genes have been widely 
characterized in PCa, available data concerning epigenetic deregulation of 
miRNAs is rather scarce. We found that miR-130a, miR-145 and miR-205 gene 
promoters are frequently methylated in PCa and HGPIN lesions, sustaining an 
important role for these alterations in PCa initiation and progression. 
 
 We found that a panel comprising miR-130a and miR-205 promoter methylation is 
able to accurately discriminate PCa from non-cancerous prostate tissues and may 
constitute a new ancillary tool for PCa diagnosis. However, the performance of 
these markers in urine samples, intended for PCa detection, is suboptimal and 
requires further improvement. Future studies should seek for meaningful 
correlations between miRNAs promoter methylation and patients’s survival, 
providing a basis for the use of this alteration as prognostic biomarkers, which may 
identify the most aggressive forms of disease. 
 
 Concerning target prediction, miR-130a, miR-205 and miR-145 seem to target 
relavant oncogenes implicated in prostate carcinogenesis. However, additional 
databases (e.g., PicTar, TargetScan or miRanda) need to be consulted to 
corroborate these preliminary findings. Moreover, microarray analysis should be 
performed using the selected target genes using PCa tissue against NPT. Finally, 
gene reporter assays need to be performed to validate putative miRNA-mRNA 
interactions, including luciferase reporter assays in PCa cellular cultures 
transfected with the selected miRNA, followed by proteome analysis. 
 
All these findings constitute the basis of further studies aimed to elucidate the role 
of epigenetically deregulated miRNAs in prostate carcinogenesis, improve 
biomarker performance and identify new therapeutic targets.  
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